WO2006034343A2 - methods for regulating neurotransmitter systems by inducing counteradaptationS - Google Patents
methods for regulating neurotransmitter systems by inducing counteradaptationS Download PDFInfo
- Publication number
- WO2006034343A2 WO2006034343A2 PCT/US2005/033826 US2005033826W WO2006034343A2 WO 2006034343 A2 WO2006034343 A2 WO 2006034343A2 US 2005033826 W US2005033826 W US 2005033826W WO 2006034343 A2 WO2006034343 A2 WO 2006034343A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- administration
- receptor
- receptors
- synaptic
- ligand
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates generally to neurotransmitter systems associated with undesirable mental and neurological conditions.
- the present invention relates more particularly to methods for regulating these neurotransmitter systems by inducing counteradaptative responses.
- Mood, mood disorders and related conditions are a result of a complex web of central nervous system events that interrelate many neurotransmitter systems.
- a most common mood disorder is depression.
- Depression is a clinical diagnosis with numerous somatic and mental symptoms, which is due to an alteration of numerous neurotransmitter systems.
- the neurotransmitter systems most commonly related with depression are the norepinephrine and serotonin systems, current research indicates that other systems, such as the substance P system, the dynorphin system (kappa receptors), and the endogenous endorphin system (mu and delta opiate receptors) are also involved in depression.
- neurotransmitter systems are also related to a whole host of other undesirable mental and neurological conditions, including bipolar disorders, obsessive-compulsive disorders, anxiety, phobias, stress disorders, substance abuse, sexual disorders, eating disorders, motivational disorders and pain disorders.
- Conventional strategies for treating neurotransmitter-linked conditions are centered on improving abnormally high or low levels of synaptic neurotransmitters.
- Conventional therapeutic agents work to directly regulate the functioning of the neurotransmitter systems.
- Such agents may be anxiolytic agents, hypnotic agents, or selective reuptake inhibitors, and include benzodiazepines (e.g., diazepam, lorazepam, alprazolam, temazepam, flurazepam, and chlodiazepoxide), TCAs, MAOIs, SSRIs (e.g., fluoxetine hydrochloride), NRIs, SNRIs, CRF modulating agents, serotonin pre-synaptic autoreceptor antagonists, 5HT 1 agonist, GABA-A modulating agents, serotonin 5H 2 c and/or 5H 2B modulating agents, beta-3 adrenoceptor agonists, NMDA antagonists, VlB antagonists, GPCR modul
- One embodiment of the present invention relates to a method of regulating a neurotransmitter system by inducing a counteradaptation in a patient, the neurotransmitter system including a type of receptor linked to an undesirable mental or neurological condition.
- the method comprises the step of: repeatedly administering to the patient a ligand for the type of receptor, each administration having an administration half-life, thereby causing the ligand to bind receptors of that type during a first time period associated with each administration, thereby inducing a counteradaptation, wherein the counteradaptation causes the regulation of the neurotransmitter system, and wherein the ratio of the administration half-life to the period between administrations is no greater than
- a method for inducing a regulation of a neurotransmitter system in a patient, the neurotransmitter system including a type of receptor linked to an undesirable mental or neurological condition.
- the method comprising the steps of: inducing a counteradaptation by giving the patient a ligand for the type of receptor; then repeatedly administering to the patient a ligand for the type of receptor, each administration having an administration half-life, thereby causing the ligand to bind receptors of that type during a first time period associated with each administration, thereby maintaining or improving the counteradaptation, wherein the counteradaptation causes the regulation of the neurotransmitter system, and wherein the ratio of the administration half-life to the period between administrations is no greater than 1/2.
- the neurotransmitter system is the SP system; the type of receptor is SP receptors; the ligand is an SP receptor agonist; the undesirable mental or neurological condition is positively linked to the receptors; and the counteradaption causes a down-regulation of the SP system.
- the neurotransmitter system is the endogenous endorphin system; the type of receptor is mu and/or delta opiate receptors;; the ligand is a mu and/or delta opiate receptor agonist; the undesirable mental or neurological condition is negatively linked to the receptors; and the counteradaption causes an up-regulation of the endogenous endorphin system.
- the neurotransmitter system is the dynorphin system; the type of receptor is kappa receptors; the ligand is a kappa receptor agonist; the undesirable mental or neurological condition is positively linked to the receptors; and the counteradaption causes a down-regulation of the dynorphin system.
- the neurotransmitter system is the serotonin system; and the counteradaption causes an up-regulation of the serotonin system.
- the type of receptor is serotonin pre-synaptic autoreceptors; the ligand is a serotonin pre-synaptic autoreceptor agonist; and the undesirable mental or neurological condition is positively linked to the receptors.
- the type of receptor is serotonin post ⁇ synaptic receptors; the ligand is a serotonin post-synaptic autoreceptor antagonist; and the undesirable mental or neurological condition is negatively linked to the serotonin post ⁇ synaptic autoreceptors.
- the neurotransmitter system is the norepinephrine system; and the counteradaption causes an up-regulation of the norepinephrine system.
- the type of receptor is norepinephrine pre-synaptic alpha-2 adrenergic receptors; the ligand is a norepinephrine pre-synaptic alpha-2 adrenergic receptor agonist; and the undesirable mental or neurological condition is positively linked to the receptors.
- the type of receptor is norepinephrine post- synaptic adrenergic receptors; the ligand is a norepinephrine post-synaptic adrenergic receptor antagonist; and the undesirable mental or neurological condition is negatively linked to the norepinephrine post-synaptic adrenergic receptors.
- a method for inducing a regulation of a neurotransmitter system, the neurotransmitter system including a type of receptors linked to an undesirable mental or neurological condition.
- the method comprising the step of: repeatedly administering to the patient a ligand for the type of receptor, each administration having an administration half-life, thereby causing the ligand to bind a substantial fraction of receptors of that type during a first time period associated with each administration, thereby inducing a counteradaptation; wherein the counteradaptation causes the regulation of the neurotransmitter system during a second time period associated with each administration, the second time period being subsequent to the first time period.
- the methods of the present invention result in a number of advantages over prior art methods.
- the methods of the present invention can be used to address a whole host of undesirable mental and neurological conditions with reduced side effects.
- the desired therapeutic benefit can be timed to coincide with a desired time of day or task to be performed by the patient.
- FIG. 1 is a graph of in vivo ligand concentration (part a) and mood vs. time (part b) according to one embodiment of the invention
- FIG. 2 is a graph of mood vs. time for several administrations of a ligand according to another embodiment of the invention.
- FIG. 3 is a graph of in vivo ligand concentration vs. time for the administration via a single injection of a ligand with a relatively long compound half-life;
- FIG. 4 is a graph of in vivo ligand concentration vs. time for the administration via time-release transdermal patch of a ligand with a relatively short compound half-life;
- FIG. 5 is a graph of in vivo ligand concentration vs. time for the administration via time-release transdermal patch of a ligand with a relatively short compound half-life, when the patch is removed during the administration;
- FIG. 6 is a graph of in vivo ligand concentration (part a) and mood vs. time (part b) according to another embodiment of the invention.
- the present invention relates generally to the regulation of neurotransmitter systems by exploiting the patient's response to a pharmaceutical agent (a "counteradaptation"), rather than by relying on the direct effect of the agent for an improved clinical effect.
- a pharmaceutical agent a "counteradaptation”
- pharmaceutical agents are chosen so that the counteradaptation is beneficial to the patient and eventually provides the desired long-term effect.
- the methods of the present invention differ from conventional methods in that the direct effect of the agent is a modulation of neurotransmitter receptors that is generally associated with a worsening of symptoms.
- the brain responds by a counteradaptation, resulting in the desired regulation of the neurotransmitter system when any direct effect of the agent wears off.
- the regulation may be any change in neurotransmitter functioning, and may be, for example, an up-regulation or a down- regulation.
- a specific acute response is induced directly in order to generate a desired long-term effect indirectly.
- euphoria-stimulating agents such as morphine and cocaine result in depression upon their withdrawal
- dysphoria-stimulating agents result in "anti-depression" upon their withdrawal.
- a neurotransmitter system is a system of natural neurotransmitter compounds and synaptic receptors that participates in central nervous system signal transmission.
- the neurotransmitter system includes a type of receptors linked to an undesirable mental or neurological condition.
- FIG. 1 includes a graph of in vivo ligand concentration versus time for a method according to one embodiment of the invention. As illustrated in FIG. 1, the method includes the step of repeatedly administering to a patient a ligand for the type of receptor, thereby causing the ligand to bind receptors of that type during a first time period associated with each administration.
- a ligand is a compound that binds to (e.g., interacts with in either a covalent or non-covalent fashion) receptors of the type of receptor, and may be, for example, an agonist for the receptor or an antagonist for the receptor.
- the binding of the ligand to the receptors induces a counteradaptation, which causes the regulation of the neurotransmitter system.
- FIG. 1 shows a couple of administrations of ligand occurring in the middle of the method, and not the first couple of administrations. Each administration is a single cycle in which the in vivo concentration of the ligand begins at a baseline level, goes up to a maximum level, and drops back down to the baseline level.
- the graph of FIG. 1 shows two such administrations.
- each administration of the ligand may be performed, for example, by giving the patient a single unit dose (e.g., pill, capsule) or injection; multiple unit doses or injections; or continuously (e.g., intravenous or slow-release patch).
- a single unit dose e.g., pill, capsule
- multiple unit doses or injections e.g., intravenous or slow-release patch.
- Examples of types of neurotransmitter systems and types of receptors with which the method may be practiced include the Substance P system, in which the type of receptors may be NK-I, NK-2 and/or NK-3 receptors; the endogenous endorphin system in which the type of receptors may be mu and/or delta opiate receptors; the dynorphin system in which the type of receptors may be kappa receptors; the serotonin system in which the type of receptors may be inhibitory serotonin pre-synaptic autoreceptors (e.g., 5HT 1A and/or 5HT 1B autoreceptors) and/or serotonin post-synaptic receptors (e.g.
- the undesirable mental or neurological condition is linked to a type of receptor in the neurotransmitter system. If the undesirable mental or neurological condition is exacerbated by the binding of the receptor to its natural neurotransmitter, then it is said to be "positively linked” to that type of receptor. Conversely, if the undesirable mental or neurological condition is improved by the binding of the receptor to its natural neurotransmitter, then it is "negatively linked" to that type of receptor.
- the undesirable mental or neurological condition of depression is negatively linked to serotonin post-synaptic receptors, because binding of these receptors to their natural neurotransmitter serotonin results in a decrease in the depression.
- the undesirable mental or neurological condition of depression is positively linked to kappa receptors, because binding of these receptors to their natural neurotransmitter dynorphin results in an increase in the depression.
- the methods of the present invention exploit the indirect counteradaptive effect to enhance or suppress neurotransmitter systems linked to undesirable mental or neurological conditions.
- the counteradaptation is the brain's natural response to the binding of the ligand.
- the initial effect of ligand binding may be a worsening of the undesirable mental or neurological condition.
- the counteradaptation causes an overall desirable regulation of the neurotransmitter system.
- the regulation of the neurotransmitter system can, in turn, provide a therapeutic benefit with respect to the undesirable mental or neurological condition.
- the regulation of the neurotransmitter system may be, for example, an increase in the counteradaptive response (as shown in FIG. 2, described below), or a maintenance of an already-induced counteradaptive response (as shown in FIG. 6, described below).
- Counteradaptations are a manner by which the central nervous system maintains homeostasis.
- the counteradaptation is a result of the body's attempt to regulate the neurotransmitter system to its original steady-state level in order to prevent its over- or under-stimulation.
- Natural neurotransmitters bind with their receptors for only a short time, and are removed almost immediately from the synapse, and therefore do not cause a counteradaptive response.
- a ligand When a ligand interacts with a receptor for a longer period of time (e.g., because the ligand has a longer binding time or is continuously administered), however, cellular mechanisms gradually occur at the receptor/neurotransmitter level that act to counteract the direct effects of the ligand-receptor binding (i.e., the counteradaptation).
- the counteradaptation may be, for example, a change in the biosynthesis or release of a natural neurotransmitter that binds to the type of receptor, a change in the reuptake of a natural neurotransmitter that binds to the type of receptor, a change in the number of the type of receptors and/or binding sites on receptors of the type of receptor, a change in the sensitivity of receptors of the type of receptor to binding by the natural neurotransmitter and/or receptor agonists, or a combination thereof.
- Chronic use of a ligand thus induces (i.e., causes) a counteradaptation by stimulating processes that oppose the initial effects of the ligand, which over time results in a decrease in the effect of ligand- receptor binding.
- the counteradaptation works to reduce the functioning of the neurotransmitter system (i.e., a "down-regulation").
- the down- regulation may occur through, for example, a decrease in the biosynthesis or release of a natural neurotransmitter that binds to the type of receptor, an increase in the reuptake of a natural neurotransmitter that binds to the type of receptor, a decrease in the number of the type of receptors and/or binding sites on receptors of the type of receptor, a decrease in the sensitivity of receptors of the type of receptor to binding by the natural neurotransmitter and/or receptor agonists, or a combination thereof.
- Any of the above-recited counteradaptive responses will work to reduce the functioning of the neurotransmitter system, and can therefore provide a therapeutic benefit with respect to an undesirable mental or neurological condition that is positively linked to the neurotransmitter system.
- the counteradaptation works to increase the functioning of the neurotransmitter system (i.e., an "up-regulation").
- the up-regulation may occur through, for example, an increase in the biosynthesis or release of a natural neurotransmitter that binds to the type of receptor, a decrease in the reuptake of a natural neurotransmitter that binds to the type of receptor, an increase in the number of the type of receptors and/or binding sites on receptors of the type of receptor, an increase in the sensitivity of receptors of the type of receptor to binding by the natural neurotransmitter and/or receptor agonists, or a combination thereof.
- Any of the above-recited counteradaptive responses will work to increase the functioning of the neurotransmitter system, and therefore provide a therapeutic benefit with respect to an undesirable mental or neurological condition that is negatively linked to the neurotransmitter system.
- Receptors in the brain are commonly regulated by a pre-synaptic negative inhibition control loop.
- a pre-synaptic negative inhibition control loop For mood-elevating post-synaptic receptors (i.e., receptors negatively linked to an undesirable mental or neurological condition), it is desirable to use repeated agonist treatment at the associated inhibitory pre-synaptic receptors.
- Repeated agonist administration at a pre-synaptic inhibitory receptor results in a down-regulation of that receptor, lessening its inhibitory response and thereby increasing neural firing at the mood- elevating post-synaptic receptors and providing an elevation of mood.
- An opposite strategy is desired for use with mood-depressing post-synaptic receptors (i.e., receptors positively linked to an undesirable mental or neurological condition).
- mood-depressing post-synaptic receptors i.e., receptors positively linked to an undesirable mental or neurological condition.
- Repeated antagonist administration at a pre ⁇ synaptic inhibitory receptor results in an up-regulation of that receptor, lessening its inhibitory response and thereby decreasing neural firing at the mood-depressing post ⁇ synaptic receptors and providing an elevation in mood.
- the direct effect of the ligand binding during the first time period will often be an initial exacerbation of the undesirable mental or neurological condition.
- the administered ligand is an antagonist for a type of receptor linked negatively to the undesirable mental or neurological condition
- the short-term effect of the binding is to block the receptors and prevent them from binding the natural neurotransmitter and firing.
- the administered ligand is an agonist for a type of receptor positively linked to the undesirable mental or neurological condition
- the short term affect of the binding is to cause the receptors to fire. Both the firing of receptors positively linked to the undesirable mental or neurological condition and the prevention of the firing of receptors negatively linked to the undesirable mental or neurological condition can cause an initial worsening of symptoms.
- FIG. 1 also includes in part (b) a graph of mood vs. time for administration of an appropriate ligand for a mood-associated receptor.
- the direct effect of ligand administration may be a worsening of mood during each first time period. This worsening of mood tapers off as the in vivo concentration of the ligand falls to its steady state level. After the ligand concentration returns to its low steady state level, the counteradaptation remains in place to provide an overall improvement in mood during a second time period associated with each administration and subsequent to the first time period.
- FIG. 2 is a graph of mood vs. time for several administrations of a ligand during a method according to the present invention. As evidenced in FIG.
- the strength of the counteradaptation may build up with time, with each administration causing additional counteradaptive response.
- an increasing therapeutic benefit may be realized with repeated intermittent administration of the ligand.
- Each administration of the ligand has an administration half-life.
- the in vivo concentration of the ligand is at a relatively low baseline level at the beginning of the administration (e.g., the swallowing of a pill, the application of a transdermal patch, or the beginning of intravenous administration), then rises to some maximum level. After reaching a maximum, the in vivo concentration of the ligand will decrease back down to the baseline level (e.g., due to metabolism/excretion of the ligand), where it remains until the next administration.
- the administration half-life is measured as the period of time between the beginning of the administration and the half-maximum point of the in vivo concentration as the concentration drops from its maximum level to the baseline level.
- the administration half-life will be a function of the compound half-life (i.e., the half-life in vivo of the ligand compound itself) as well as of the route of administration.
- FIG. 3 is a graph of in vivo concentration versus time for a single administration via injection of a ligand with a relatively long compound half-life. Because the injection gets the ligand into the bloodstream very quickly, the administration half-life approximates the compound half-life.
- a ligand with a much shorter compound half life e.g., a peptide
- the administration half-life may be, for example, less than about a week, less than about three days, or less than about a day. More desirably, the administration half-life is less than about sixteen hours; less than about twelve hours, less than about eight hours; or less than about four hours. In certain embodiments of the invention, especially those using a ligand having a relatively long compound half-life, the administration half-life may be greater than about four hours; greater than about twelve hours; greater than about sixteen hours; or greater than about thirty hours.
- the ligand has a compound half-life, defined as the in vivo half life of the ligand and its active metabolites (i.e., metabolites that are active at receptors of the type of receptor), divorced from any effects due to the route of administration.
- a compound with a relatively short compound half-life For example, in certain embodiments of the invention the compound half-life is less than about a week, less than about three days, or less than about a day. More desirably, the compound half-life is less than about sixteen hours; less than about twelve hours, less than about eight hours; or less than about four hours; or less than one hour.
- the compound half-life of the ligand is greater than about four hours; greater than about twelve hours; greater than about sixteen hours; or greater than about thirty hours.
- the period between administrations is desirably selected so as to maximize the counteradaptive response to the ligand while maintaining an acceptably low and tolerable direct effect of ligand-receptor binding.
- the administration of the ligand may be performed daily.
- the period between administrations is two days or greater; three days or greater; five days or greater; one week or greater; two weeks or greater; or one month or greater.
- the dose of the ligand at each administration is selected to be sufficient to trigger a counteradaptive response, but low enough that direct effects of ligand-receptor binding are low and tolerable to the patient.
- a ligand having a compound half-life greater than about twelve hours in order to increase the counteradaptation it may be desirable to repeatedly administer a second ligand for the type of receptor, with each administration of the second ligand having an administration half-life of less than about eight hours.
- a ligand having a twenty-four hour compound half-life is administered every three days with a twenty four hour administration half-life, and a second ligand is administered daily with a six hour administration half-life.
- the second ligand is desirably a receptor agonist
- the second ligand is desirably a receptor antagonist
- the second ligand is desirably a receptor antagonist.
- the ratio of administration half-life to the period between administrations is desirably selected to maximize the counteradaptation while keeping any direct effects of ligand binding during the first time period at a low and tolerable level.
- the ratio of the administration half-life to the period between administrations is no greater than 1/2.
- the ratio of the administration half-life to the period between administrations is no greater than 1/3.
- the ratio of the administration half-life to the period between administrations is no greater than 1/5; no greater than 1/8; or no greater than 1/12. It may be, however, desirable to administer the ligand relatively often, in order to maintain a desired level of counteradaptation.
- the ratio of administration half-life to the period between administrations may be greater than 1/100; greater than 1/50; greater than 1/24; greater than 1/12; greater than 1/8; greater than 1/5; greater than 1/4; or greater than 1/3.
- a substantial fraction of the receptors of the type of receptor are bound to the ligand during the first time period associated with each administration, so as to cause a counteradaptation to the ligand binding. For example, at least about 30%, at least about 50%, at least about 75%, or at least about 90% of the receptors of the type of receptor are bound by the ligand during each first time period.
- each first time period associated with each administration is desirably long enough to cause a substantial counteradaptation.
- each first time period is desirably at least about five minutes in duration; at least about thirty minutes in duration; at least about an hour in duration; at least about two hours in duration; or at least about four hours in duration.
- each first time period is about eight hours in duration.
- the first time period is desirably less than about twenty four hours in duration; less than about sixteen hours in duration; less than about twelve hours in duration; less than about eight hours in duration; or less than about six hours in duration.
- a substantial fraction of the receptors remain unbound to the ligand during a second time period associated with each administration and subsequent to the first time period.
- a low level of ligand-receptor binding allows the patient to enjoy the effects (e.g., the therapeutic benefit) of the counteradaptation without interference from any ill effects of direct ligand binding.
- no more than about 50%, no more than about 25%, no more than about 10% of the receptors are bound to the ligand during each second time period.
- the second time period associated with each administration is the time during which a substantial fraction of the receptors of the type of receptor are unbound to the ligand.
- each second time period is desirably as long as possible.
- each second time period is desirably at least about two hours in duration; at least about ten hours in duration; or at least about fifteen hours in duration.
- each second time period is desirably no more than about twenty hours in duration; no more than about thirty hours in duration; or no more than about fifty hours in duration.
- the dosage is increased with a period between increases of no less than a week; no less than two weeks; no less than three weeks; no less than a month; no less than two months; no less than three months; no less than six months, or no less than one year.
- the dose is desirably increased by at least about 5%; at least about 10%; at least about 25%; at least about 50%; or at least about 100% of the initial dose. It may, however, be desirable to maintain the maximum dosage within certain limits.
- the maximum dosage may be within three hundred times the initial dosage, within one hundred times the initial dosage, within fifty times the initial dosage, or within twenty times the initial dosage.
- a dosing schedule low doses of a ligand are given for one, two, or three weeks. These initial doses are high enough to induce a counteradaptive response, but low enough to cause only minimal direct effects due to ligand-receptor binding. The dose is then increased. The increase may be as small as 10%; for more rapid induction of a counteradaptive response, however, it is desirable to at least double the initial dose. After four to six weeks the dosage is again increased. This pattern is followed every one, two, four or six months. The endpoint for the maximum dosage will depend on individual tolerance to the ligand and the development of side effects and direct effects from the larger doses.
- the administration of the ligand may be desirable to time the administration of the ligand so that the first time period occurs during a time when adverse effects on the patient will be minimized.
- the patient will not notice a decrease in mood if she is asleep.
- at least 40%; at least 60%; or at least 85% of the first time period desirably occurs while the patient is asleep.
- each administration of the ligand is performed more than one hour before the patient goes to bed.
- a patient who has been administered a ligand daily for two or three months and has developed a counteradaptation and some associated improvement in mood is administered.
- the time of ligand administration could be moved so that the desired time would fall within the second time period associated with that administration.
- an appropriate ligand e.g., naloxone, a mu and/or delta opiate receptor antagonist with a compound half-life of one hour
- the direct effect of naloxone-receptor binding would last only a couple of hours, leaving only the good mood caused by the counteradaptation by 6 p.m.
- the administration of the ligand is desirably repeated enough to build up a suitably large counteradaptive effect.
- the administration is desirably performed at least five times, at least ten times, at least twenty- five times, or at least fifty times.
- Each administration of the ligand may be performed orally, transdermally, through inhalation, subcutaneously, intravenously, intramuscularly, intraspinally, intrathecally, transmucosally, or using an osmotic pump, a microcapsule, an implant or a suspension.
- the skilled artisan will select the route of administration based upon the identity of the ligand, its compound half-life, the desired dose and the desired administration half-life.
- a rectal suppository having a rapidly-absorbing outer covering and a more slowly absorbing center could be used for such an administration.
- the loading dose could be given sublingually, and the gradually absorbed dose could be given transdermally via patch.
- a carrier in the blood may be used to increase the administration half-life of the ligand once it is in circulation.
- U.S. Patents 6,610,825 and 6,602,981 each of which is incorporated herein by reference in its entirety, describe a method by which ligands are bound to blood cells or proteins in order to extend their administration half-life.
- Adessi et al (Curr Med Chem, 9(9); May, 2002;963-978) describe a method by which to stabilize peptide ligands.
- the undesirable mental or neurological condition may be any condition linked to the neurotransmitter system. Examples of such conditions include chronic pain, mood disorders, eating disorders, anxiety disorders, motivational and performance problems, inflammatory conditions, nausea, emesis, urinary incontinence, skin rashes, erythema, and eruptions. More examples of undesirable mental or neurological conditions are described below.
- anxiolytic agent in combination with the ligand, so as to reduce any direct effects of ligand-receptor binding.
- the anxiolytic agent may especially help mitigate the effects of ligand-receptor binding on the patient's sleep.
- the anxiolytic agent may, for example, affect a GABA pathway.
- the anxiolytic agent may be, for example, a benzodiazepine such as diazepam, lorazepam, alprazolam, temazepam, fiurazepam, and chlodiazepoxide.
- a hypnotic agent or a selective serotonin reuptake inhibitor in combination with the ligand, so as to reduce any direct effects of ligand-receptor binding.
- a hypnotic agent or a selective serotonin reuptake inhibitor may be administered at the same time as the ligand, or at a different time. It may also be desirable to add tryptophan to the patient's diet, as described in U.S. Patents 4,377,595 and 5,958,429, each of which is incorporated herein by reference in its entirety.
- Administration of such an agent is especially desirable when it is an agonist for a type of receptor that has been increased in number and/or sensitivity through a counteradaptation, or is an antagonist for a type of receptor that has been decreased in number and/or sensitivity through a counteradaptation.
- Examples of conventional pharmaceutical agents that may administered in combination with the ligand include TCAs, MAOIs, SSRIs 5 NRIs, SNRIs, CRF modulating agents, serotonin pre-synaptic autoreceptor antagonists, 5HTi agonist,dynorphin antagonists, GABA-A modulating agents, serotonin 5H 2 c and/or 5H 2B modulating agents, beta-3 adrenoceptor agonists, NMDA antagonists, VlB antagonists, GPCR modulating agents, or substance P antagonists.
- the additional pharmaceutical agent has a relatively short administration half-life, so that it can be administered during the second time period, with its effect substantially absent by the next administration of the ligand. Such an administration regimen maintains a high level of counteradaptation, while maximizing the effect of the pharmaceutical agent during the second time period.
- the ligand when the ligand is a receptor agonist, it may be desirable to administer an antagonist for the type of receptor during one or more of the second time periods associated with each administration and subsequent to the first time period. However, the antagonist for the type of receptor is desirably not administered during the first time period associated with each administration. Similarly, when the ligand is a receptor antagonist, it may be desirable to administer an agonist for the type of receptor during one or more of the second time periods associated with each administration and subsequent to the first time period. However, the agonist for the type of receptor is desirably not administered during the first time period associated with each administration. Preferably the antagonist has an in vivo half life of less than 12 hours, less than 8 hours, or less than 6 hours, such that it would not interfere with the subsequent administration of the agonist.
- FIG. 6 Another embodiment of the present invention is illustrated by the graphs of in vivo ligand concentration (part a) and mood vs. time (part b) of FIG. 6.
- a counteradaptation is first induced by giving the patient one or more doses of a ligand for the type of receptor. As shown in FIG. 6, this could be through repeated or continuous administration of high doses of the ligand. Relatively high, long-term doses of the ligand will induce a strong counteradaptive effect, but may cause the patient to suffer marked direct effects from ligand-receptor binding, as shown in the graph of mood vs. time of FIG. 6. In such cases, it may be desirable to keep the patient hospitalized during the initial induction of the counteradaptive response. After the counteradaptive response is induced, it is maintained repeatedly administering the ligand to the patient with a ratio of administration half-life to period between administrations no greater than 1/2. The repeated administration may be performed substantially as described above.
- the methods of the present invention may be used to improve undesirable mental and neurological conditions, even if they are not able to cure them.
- the methods of the present invention may make undesirable mental and neurological conditions more amenable to conventional therapies.
- the improved mood caused by the use of the methods of the present invention may help improve the depression.
- the use of conventional antidepressants may also be made more efficacious.
- the regulation of the neurotransmitter acts to suppress tumor growth and/or metastasis, and may make conventional cancer therapies and/or the immune system better able to eliminate the cancerous growth.
- the therapeutic benefits caused by the regulation of the neurotransmitter may be, for example, a decrease in the severity of the symptoms associated with the mental and neurological condition; an eradication of the symptoms associated with the mental and neurological condition; or an increase in a mood that masks the symptoms associated with the mental and neurological condition.
- the methods according to the present invention may be used therapeutically to address an undesirable mental or neurological condition in a patient.
- the methods of the present invention may be used to treat a pre-existing undesirable mental or neurological condition in a patient.
- the methods may also be used to reduce any future undesirable mental or neurological condition that is anticipated to occur, for example, due to future physical exertion, physical trauma, mental trauma, or medical procedure.
- the neurotransmitter system is the Substance P ("SP") system, which includes as neurotransmitters the neurokinins Substance P, NKA and NKB.
- SP is a polypeptide and is known to act as a neurotransmitter and mediator for pain sensations. It is a member of the tachykinin family, which is a set of polypeptides having a similar C-terminal and a varying N-terminals with varying SP-like activity.
- the SP receptors include NK-I, NK-2 and NK-3 receptors. SP preferentially binds to NK-I receptors, NKA preferentially binds to NK-2 receptors, and NKB preferentially binds to NK-3 receptors.
- SP and its receptors are found primarily in the brain and spinal cord tissue.
- SP receptors are found in an area called the dorsal horn, which is a primary site for pain signals to be transmitted to the brain.
- SP and its receptors are found in large concentrations in the hypothalamus and the amygdala, areas associated with affective behavior, anxiety and response to stress, and pain.
- SP is also implicated in nausea and emesis, defensive behavior, cardiovascular tone, salivary secretion, inflammation, smooth muscle contraction and vasodilation, as well as in numerous mental conditions such as schizophrenia, manic depressive psychosis, sexual dysfunction, drug addiction, cognitive disorders, locomotive disorders, and depression.
- the type of receptor is SP receptors, which are positively linked to undesirable mental and neurological conditions
- the ligand is an SP receptor agonist.
- the counteradaptation causes a down-regulation of the SP system, and may be at least one of a decrease in the biosynthesis or release of SP, NKA and/or NKB at the receptor terminals or by the pituitary gland; a decrease in the number of the receptors and/or binding sites on the receptors; or a decrease in the sensitivity of the receptors to binding by SP receptor agonists and/or SP, NKA and/or NKB.
- the SP receptor agonist may be, for example, peptide-based.
- the SP receptor agonist is an analogue of SP, NKA, and/or NKB, or a pharmaceutically acceptable salt or derivative thereof.
- the SP receptor agonist may be Substance P; Substance P, free acid; Biotin-Substance P; [Cys 3 ' 6 , Tyr 8 , Pro 9 ]-Substance P; (Disulfide bridge: 3-6), [Cys 3 ' 6 , Tyr 8 , Pro 10 ]-Substance P; (Disulfide bridge: 3-6), [4-Chloro-Phe 7 ' 8 ]-Substance P; [4-Benzoyl-Phe 8 ]-Substance P; [Succinyl-Asp 6 , N-Me-Phe 8 ]-Substance P (6-l l)(Senktide); [Tyr 8 ]-Substance P; [Tyr 9
- the SP receptor agonist may be an ⁇ KA or ⁇ KB analogue having a C-terminal heptapetpide similar to ⁇ KA(4-10) or NKB(4-10), or a pharmaceutically acceptable salt or carrier thereof.
- the SP receptor agonist may be [GIn 4 J-NKA, [Gln 4 ]-NKA(4-10), [Phe 7 ]-NKA, [Phe 7 ]-NKA(4-10), [He 7 J-NKA, [Ile7]-NKA(4-10), [Lys 5 ,MeLeu 9 ,Nle 10 ]-NKA(4-10), [Nle 10 ]-NKA(4-10), ⁇ -Ala 8 ]-NKA(4- 10), [Ala 5 ]-NKA(4-10), * [GIn 4 J-NKB, [Gln 4 ]-NKB(4-10), [Phe 7 ]-NKB, [Phe 7 J-NKB(4- 10), [Ile 7 ]-NKB, [Ile7]-NKB(4-10), [Lys 5 ,MeLeu 9 ,Nle 10 ]-NKB(4-10), [Nle 10 ]-NKB(4-10), ⁇ -
- the SP receptor agonist may be [Arg]-NKB, an NKA or NKB analogue having VaI 7 replaced with MePhe, or a pharmaceutically accepted salt or carrier thereof.
- Other SP receptor agonists that may be used in the present invention are SR 48968, an NK2 receptor antagonist ((S)-N-methyl-N [4-(4-acetylamino-4-[phenyl piperidino)-2- (3,4-dichlorophenyl)-butyl] benzamide]) as well as those described in U.S.
- the initial dosage (i.e., the dosage at the first administration) of the SP receptor agonist is desirably high enough to induce a counteradaptive effect, but not so high as to cause intolerable direct effects from ligand-receptor binding.
- the initial dosage of the SP receptor agonist may be between about 0.5 pmol/kg/min and about 20 pmol/kg/min for continuous dosing during the first time period.
- the initial dosage of the SP receptor agonist is between 3 pmol/kg/min and 10 pmol/kg/min for continuous dosing during the first time period.
- the present invention is not limited to the use of peptide-based SP receptor agonists.
- Other SP receptor agonists including substantially or wholly non-peptidic SP receptor agonists (e.g., those described in Chorev et al., Biopolymers, May 1991; 31(6):725-33), which is hereby incorporated herein by reference in its entirety) may be used in the methods of the present invention.
- the SP receptor agonist may be administered using any appropriate route.
- Transmucosal administration is an especially desirable method for administering SP receptor agonists.
- the administration may be sublingual or via rectal suppository. It may be desirable to administer the SP receptor agonist using both a rapidly absorbed loading dose (in order to get a fast binding of the SP receptors), and a gradually absorbed dose (in order to maintain a desired level of agonist-receptor binding over the desired length of the first time period).
- a rectal suppository having a rapidly-absorbing outer covering and a more slowly absorbing center could be used for such an administration.
- the loading dose could be given sublingually, and the gradually absorbed dose could be given transdermally via patch.
- Other routes include intraspinal or intrathecal administration for pain.
- an SP receptor antagonist is not administered during the first time period associated with each administration. In certain embodiments of the invention, however, an SP receptor antagonist is administered during one or more of the second time periods.
- SP receptor antagonists along with suggested dosages are as follows: SR 48968 ((S)-N-methyl-N [4-(4-acetylamino-4-[phenyl piperidino)-2-(3,4- dichlorophenyl)-butyl] benzamide]); Osanetant and compounds described in US 5,972,938; 6, 576, 638; 6,596,692; 6,509,014; 6,642,240; 6,841,551; 6,177,450; 6,518,295; US 6,369,074; AND US 6,586,432; AND WO 95/16679; 95/18124; 95/23798.
- SP (NK 1 ) receptor antagonists include: L-760735 ([l-(5- ⁇ [(2i?,3S)-2-( ⁇ (li?)- l-[3,5-bis(trifluoromethyl)phenyl]ethyl ⁇ oxy)-3-(4-phenyl)morpholin-4-yl]methyl ⁇ -2H- l,2,3-triazol-4-yl)-N,N-diniethylmethanamine]) (See Boyce, S, et al. Neuropharmacology.
- SSR240600 [(R)-2-(l- ⁇ 2-[4 ⁇ 2-[3,5- Bis(trifluoromethyl)phenyl]acetyl ⁇ -2-(3,4-dichlorophenyl)-2-mo ⁇ holinyl]ethyl ⁇ -4- piperidinyl)-2-methylpropanamide], a Centrally Active Nonpeptide Antagonist of the Tachykinin Neurokinin 1 Receptor: II.
- NKP608 [quinoline-4-carboxylic acid [trans-(2R,4S)-l-(3,5-bis-trifluoromethyl-benzoyl)- 2-(4-chloro-benzyl)-piperidin-4-yl]-amide)] (see Spooren WP, et al., Eur J Pharmacol.
- Suitable but non-limiting initial dosages for SP receptor antagonists include about 12 mg/kg/hour/administration for 8 hours of L-760735 (via iv); about 30 ug/kg/hour/administration for 8 hours of CP-96,345 (via iv); between about 0.1 to 10 mg/kg/administration of SSR240600 (via ip or po); between about 0.01 to 0.1 mg/kg/administration of NKP608 (via po); between about 1 to 10 mg/kg/administration of L-AT; between about 0.01 to 3 mg/kg/administration of MK-869; between about 1 to 30 mg/kg of L-742,694; between about 1 to 10 mg/kg/administration of L-733,060; between about 3 to 30 mg/kg/administration of CP-99,994 or CP-122,721; and about 100 mg/administration of Saredutant (via po).
- the SP neurotransmitter system is positively linked to a wide variety of undesirable mental and neurological conditions.
- undesirable mental and neurological conditions include chronic pain, mood disorders, eating disorders, anxiety disorders, motivational problems, substance abuse disorders, inflammatory conditions, nausea or emesis (e.g., arising from chemotherapy), urinary incontinence, skin rashes, erythema, eruptions, fibromyalgia, chronic fatigue syndrome, chronic back pain, chronic headaches, chronic cancer pain, shingles, reflex sympathetic dystrophy, neuropathy, inflammatory pain, pain that is anticipated to occur in the future (e.g., from a medical procedure or physical exertion), major depressive disorders, post-traumatic depression, temporary depressed mood, manic- depressive disorder, dysthymic disorder, generalized mood disorder, anhedonia, non ⁇ organic sexual dysfunction, overeating, obesity, anorexia, bulimia, generalized anxiety state, panic disorders, phobias, obsessive-compulsive disorder, attention deficit hyperactivity disorder, Tourette's Syndrome,
- Mood is mediated through the SP system.
- Increased levels of SP are found in clinically depressed patients.
- Substance abusers have elevated levels of SP and, for those times when they are not on the abused substance, generally have a depressed and/or dysphoric mood.
- Clinical depression and substance abuse are thus both associated with an up regulation of the SP system.
- the pleasurable experiences of morphine are absent in mice that lack the SP receptor. Such mice do not become addicted to morphine (Murtra, et al., Nature 405, 180-183, May 11, 2000).
- opiates alone cannot induce euphoria the Murtra study suggests that the SP system is the final pathway by which opiate euphoria is mediated.
- the fact that SP antagonists can acutely improve mood is consistent with this finding. Anxiety, response to stress, sexual dysfunction and eating disorders are largely related to mood, and are therefore also affected by the SP system.
- Methods of the present invention using SP receptor agonists as ligands may be used to address undesirable mental or neurological conditions in patients.
- the methods of the present embodiment of the invention may be used to address any of the above-listed conditions.
- the methods according to the present embodiment of the invention may also be used as an adjunct treatment for cancer (e.g., to decrease tumor growth and metastasis).
- the methods of the present invention could also be used with an SP agonist in chronic recurring pain situations such as migraine headaches.
- the SP system is up-regulated in chronic pain syndromes, they may also be treated using the methods of the present invention with an SP agonist.
- Such chronic pain syndromes include pain due to nerve injury, neuropathies, chronic low back pain, reflex sympathetic dystrophy, cancer pain, shingles and arthritis.
- the methods of the present invention can be used with SP agonists in the prophylaxis of pain prior to an event that is associated with pain.
- the methods of the present invention may be used in order to decrease post-operative pain and also to increase post-operative response to narcotic pain medications, which results in a lower dose of narcotics to obtain an analgesic effect.
- an SP agonist could be used in the methods of the present invention prior to such pain-inducing competitive events such as football, hockey, and boxing.
- An SP agonist could be used prior to any competitive event, such as long distance running in order to reduce pain perceptions that are inevitable with such muscle and leg overuse activities. A reduced pain response ultimately allows the athlete to push him/her self to a greater extent, resulting in an improved performance.
- the methods of the present invention may also be used with SP agonists in order to address anxiety, stress response, sexual dysfunction and eating disorders may be improved with the SP agonist CAT protocol. These conditions are largely related to mood, thus an improvement in conditions such as these are indirectly related to overall mood as opposed to a direct effect.
- the methods of the present invention may also be used with SP agonists in order to address any or all addictive disorders.
- the methods of the present invention can be used to address the abuse of substances such as narcotics, alcohol, nicotine/ cigarettes, stimulants, anxiolytics, CNS depressants, hallucinogens and marijuana.
- gambling and electronic gaming addictions follow the same brain abnormalities as do substance abuse problems, and can also be addressed using the methods of the present invention.
- the methods of the present invention may also be used with SP agonists in order to address asthma by decreasing the severity of asthma attacks.
- An inhalational route of administration may be used in order to concentrate the counteradaptive effect in the lungs where it is most needed.
- the methods of the present invention may also be used with SP agonists in order to decrease the inflammatory response in any one of a number of inflammatory conditions such as arthritis, rhinitis, conjunctivitis, inflammatory bowel disease, inflammation of the skin and mucosa and acute pancreatitis.
- the methods of the present invention may also be used with SP agonists in order to address nausea/emesis, especially that associated with chemotherapy for cancer, and urinary incontinence.
- the neurotransmitter system is the endogenous endorphin system, which includes as neurotransmitters the endorphins that bind preferentially to mu and/or delta opiate receptors.
- Endorphins are endogenous opiate- like compounds that act through their effects on the binding of opiate receptors.
- Mu and delta opiate receptors act in unison, and are stimulated by opiate and opiate-like compounds. Mu receptors primarily modulate pain, but also modulate mood. Delta receptors have the opposite focus, primarily modulating mood, but also modulating pain.
- the type of receptor is mu and/or delta opiate receptors, which are negatively linked to undesirable mental and neurological conditions.
- Mu opiate receptors are associated primarily with lower levels of pain when stimulated, while delta opiate receptors are associated primarily with euphoria when stimulated.
- the ligand is a mu and/or delta opiate receptor antagonist, and the counteradaptation causes an up-regulation of the endogenous endorphin system.
- the counteradaptation may be, for example, an increase in the biosynthesis or release of endorphins at receptor terminals and/or by the pituitary gland; an increase in the number of the receptors and/or endorphin binding sites on the receptors; an increase in the sensitivity of the receptors to binding by mu and/or delta receptor agonists and/or endorphins; or a combination thereof.
- the method according to the present embodiment of the invention may be practiced using a specific mu receptor antagonist or a specific delta receptor antagonist.
- the method may be practiced using a specific mu receptor antagonist such as clocinnamox mesylate, CTAP, CTOP, etonitazenyl isothiocyanate, ⁇ -funaltrexamine hydrochloride, naloxonazine dihydrochloride, Cyprodime, and pharmaceutically acceptable salts, analogues, and derivatives thereof.
- the method may also be practiced using specific delta receptor antagonists such as naltrindole, N-benzylnaltrindole HCl, BNTX maleate, BNTX, ICI-154,129, ICI-174,864 (N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH, where Aib is alpha-amino-isobutyric acid), naltriben mesylate, SDM25N HCl, 7-benzylidenenaltrexone, and pharmaceutically acceptable salts, analogues, and derivatives thereof.
- specific delta receptor antagonists such as naltrindole, N-benzylnaltrindole HCl, BNTX maleate, BNTX, ICI-154,129, ICI-174,864 (N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH, where Aib is alpha-amino-isobuty
- non-specific mu and/or opiate antagonists such as naloxone and naltrexone
- Non-limiting representative examples of non-specific opiate antagonists include Nalorphine, nalbuphine, levallorphin, cyclazocine, diprenorphine
- mu and/or delta opiate receptor antagonists useable in the methods of the present invention include those described in U.S. Patents 5,922,887; 4,518,711; 5,332,818; 6,790,854; 6,770,654; 6,696,457; 6,552,036; 6,514,975; 6,436,959; 6,306,876; 6,271,239; 6,262,104; 5,552,404; 5,574,159; 5,658,908; 5,681,830; 5,464,841; 5,631,263; 5,602.099; 5,411,965; 5,352,680; 5,332,818; 4,910,152; 4,816,586; 4,518,711; 5,872,097; 5,821,219; 5,326,751; 4,421,744; 4,464,358; 4,474,767; 4,476,117; 4,468,383; 6,825,205; 6,455,536; 6,740,659; 6,713,488;
- the mu and/or delta opiate receptor antagonist is naloxone, naltrexone, nalmefene, or nalbuphine, or a pharmaceutically acceptable salt or derivative thereof.
- Naltrexone is a desirable mu and/or delta receptor antagonist, but may not be usable in all situations due to its long compound half-life (48-72 hours); while naltrexone itself has a half-life of 9-10 hours, its active metabolites (e.g. 6-beta-naltrexol and 2-hydroxy-3-methoxynaltrexol) have much longer half-lives.
- Naloxone is an especially desirable mu and/or delta receptor antagonist for use in the present embodiment of the invention.
- Naloxone has a compound half-life of about an hour, but cannot be given orally.
- Naloxone can be given intravenously or through a transdermal patch, desirably using a time-release formulation. Suitable transdermal patches are described in U.S. Patent 4,573,995, which is hereby incorporated herein by reference in its entirety.
- the initial dosage of the mu/and or delta opiate receptor is desirably high enough to induce a counteradaptive effect, but not so high as to cause the patient intolerable direct effects.
- the initial dosage of the mu and/or delta opiate receptor antagonist may be equivalent to between about 2 mg/administration and about 200 mg/administration of naloxone.
- the initial dosage of the mu and/or delta opiate receptor antagonist is equivalent to between about 10 mg/administration and about 100 mg/administration of naloxone.
- the initial dosage may be between 5 and 500 mg/administration. Desirably, the initial dosage is between 10 and 50 mg/administration. In certain embodiments of the invention, each dosage of naloxone is greater than 10 mg/administration; greater than 10.5 mg/administration; greater than 11 mg/administration; or greater than 15 mg/administration. Desirably, the initial dose of naloxone is at least about 30 mg/administration (over 8 hour period), as this amount results in a complete blockade of opiate receptors. Desirably, the maximum dosage of naloxone is no greater than 3000 mg/administration.
- the initial dosage of naloxone is 30 mg/administration over an 8 hour period. After two weeks, the dosage is doubled. After another two weeks, the dosage is increased to 120-160 mg/administration. After another month, the dosage is increased to 300 mg/administration, then to 500-600 mg/administration after another two months. After another two months, the dosage is increased to 1000 mg/administration, then to 1500-2000 mg/administration after another two months. Alternatively, a much larger initial dose (e.g., 100-500 mg/administration) could be used in order to build up a counteradaptation more quickly. A low dose of naltrexone (e.g., 10-25 mg/administration) could be used along with the naloxone to realize an additional counteradaptive effect.
- naltrexone e.g. 10-25 mg/administration
- naltrexone In one example of a dosing regimen for naltrexone, an initial dosage of 10-25 mg naltrexone is given daily. Alternatively, larger doses (e.g., 25-200 mg/administration) are given once, twice, or thrice weekly. With larger doses of naltrexone, the first time period will be relatively long, and may occasionally overlap with the waking hours of the patient.
- the mu and/or delta opiate receptor antagonist may be administered orally, transdermally, intraspinally, intrathecally, via inhalation, subcutaneously, intravenously, intramuscularly, or transmucosally, or via osmotic pump, microcapsule, implant, or suspension.
- it may be desirable to administer it using a time-release or slow-release formation, or transdermally (e.g., using a patch) in order to provide an administration half-life of sufficient length.
- the mu and/or delta opiate receptor antagonist When the mu and/or delta opiate receptor antagonist is administered transdermally or using a time- release or slow-release formulation, it is desirably released over a time period between two and twelve hours in duration; between two and six hours in duration; or between six and twelve hours in duration.
- a transdermal patch for naloxone, naltrexone and nalbuphine is disclosed in U.S. Patent 4,573,995, which is hereby incorporated herein by reference in its entirety.
- the two types of antagonist may be administered substantially simultaneously or sequentially. Because the non-specific antagonists generally provide a greater counteradaptive effect than do specific mu or delta opiate antagonists, it is desirable to administer non-specific antagonists in the early stages of the method.
- the body develops a tolerance to anti-opiates about eight days after first administration, it may be desirable to increase the dosage of the mu and/or delta opiate receptor antagonist with time. For example, it may be desirable to increase the dosage with a period of between a week and two weeks.
- an endorphin receptor agonist is not administered during the first time period associated with each administration. In certain embodiments of the invention, however, an endorphin receptor agonist is administered during one or more of the second time periods.
- Suitable but non-limiting examples of endorphin agonists include opiates such morphine, codeine, hydrocodone, fentanyl, and oxycodone. Morphine may be administered at dosages of 1 - 20 - 50 mg i.v.
- transdermal i.v., SQ, IM, or pump
- Fentanyl may be administered at dosages of 0.1 - 0.5 mg gradual release over 8 hours via any suitable means such as transdermal, SQ, IM, or pump
- Codeine may be administered at dosages of 10 - 100 mg p.o. every 4 - 6 hours
- Hydrocodone may be administered at dosages of 5 - 25 mg p.o. every 4-6 hours
- Oxycodone may be administered at dosages of 5 - 100 mg p.o. every 4 hours by any suitable means such as slow release transdermal, i.m., or SQ over 4-8 hours).
- Enkephalins having an amino acid sequence of H-Tyr-Gly-Gly-Phe-Met-OH or H- Tyr-Gly-Gly-PheLeu-OH or any active analogues of these amino acid sequences with pharmacologically accepted carriers. Enkephalins may be administered at dosages of 1.0 ⁇ g/hr continuous release (transdermal, i.v., SQ, i.p. i.m. infusion pump).
- Beta endorphin (a 31 amino acid peptide) or any and all active analogues, eg., beta- endorphin-(l-26), [D-Ala2]beta-endorphin or [Leu5]beta-endorphin with accepted pharmacologically accepted carriers.
- Beta endorphins may be administered at dosages of 1.0 ⁇ g/hr continuous release (e.g. transdermal, i.v., SQ, i.p. i.m. infusion pump).
- Mu selective agonists such as Carfentanil which may be administered at a dosage of 1-25 ⁇ g/kg; [D-Ala2, NMe-Phe4, Gly-ol5] enkephalin and any active analogue with pharmacologically accepted carriers.
- the enkephalins may be administered at a suggested dosage of 1.0 ⁇ g/hr continuous release (e.g. i.v., i.m., SQ, pump, or transdermal).
- DPDPE [D-Pen2,D-Pen5]enkephalin); SB-235863; and SNC 80.
- DPDPE may be administered at a suggested dosage of 1.0 - 5.0 ⁇ g/hr continuous release (e.g., i.v., i.m., SQ, pump, or transdermal).
- SB-235863 [8i?-(4b 1 S r *,8aO-
- SNC 80 may be administered at a dosage of 50 - 75 mg/kg slow release over several hours, transdermal, i.p. SQ, pump, etc.) See EJ Bilsky, et al., Pharmacology and Experimental Therapeutics, Volume 273, Issue 1, pp. 359-366, 04/01/1995.
- the endogenous endorphin system and its mu and/or delta opiate receptors are negatively linked to a wide variety of undesirable mental and neurological conditions.
- undesirable mental and neurological conditions include pain, mood disorders, eating disorders, anxiety disorders, motivational problems, substance abuse disorders, insufficient motivation or performance, immune system-related conditions, wounds in need of healing, pain that is expected to occur in the future (e.g., due to a future operation or due to future physical exertion), chronic pain syndromes, acute pain, fibromyalgia, chronic fatigue syndrome, chronic back pain, chronic headaches, shingles, reflex sympathetic dystrophy, neuropathy, inflammatory pain, chronic cancer pain, major depressive disorders, post traumatic depression, temporary depressed mood, manic-depressive disorders, dysthymic disorders, generalized mood disorders, anhedonia, non-organic sexual dysfunction, overeating, obesity, anorexia, bulimia, a generalized anxiety state, panic disorders, Tourette's Syndrome, hysteria sleep disorders, breathing-related sleep disorders, lack of motivation
- the up-regulation of the endogenous endorphin system desirably causes a therapeutic benefit with respect to the undesirable mental or neurological condition.
- the endogenous endorphin system is implicated in pain because endorphins can bind to pain-mediating opiate receptors and decrease the synthesis of SP, a pain- inducing substance.
- the endogenous endorphin system has also been implicated in stress (U.S. Patents 5,922,361 and 5,175,144), wound healing (Vinogradov VA, Spevak SE, et al, Bi and U.S.
- Patent 5,395,398) substance abuse, eating disorders (Full & fulfilled : the science of eating to your soul's satisfaction, by Nan Allison; Carol Beck, Publisher: Nashville, TN : A & B Books, ⁇ 1998, ISBN: 0965911799), motivational problems (Tejedor-Real, P, et al, Eur J Pharmacol. 1998 JuI 31;354(l):l-7); immune response (Wybran, Fed Proc. 1985 Jan;44(l Pt l):92-4, and U.S. Patent 5,817,628) and cancer (Zagon, IS, et al., Cancer Lett, 1997; 112:167-175; U.S. Patents 6,737,397; 6,136,780; and 4,801,614).
- the endogenous endorphin system is also implicated in mood.
- Euphoria is the most recognizable emotional effect of opioids, which gives one an elevated feeling of well-being and care-free.
- Euphoria is modulated by endogenous endorphins. Endorphins are released with pleasurable experiences such as eating, exercise, winning an event, romantic encounters. It is thought that the endorphin release generates a feeling of well- being as a 'reward', which acts as a motivational mechanism in order to inspire an individual to fulfill nutritional and reproductive requirements.
- Another function of the endogenous endorphin system with respect to mood is to decrease anxiety, especially with regards to stress response.
- Peptides as Mediators. In H. P. Rang & M. M. Dale, Pharmacology, Churchill Livingstone, New York.) demonstrates that endorphins are released at times of emotional stress, which acts to induce euphoria in order that anxiety is reduced.
- Both endogenous endorphins and synthetic opiates may induce euphoria.
- endogenous endorphins are rapidly degraded at their synapse and receptor sites, such that the effect is short term. With a short term effect there is no development of tolerance or dependency. Synthetic opiates, such as narcotics, have a much longer reactive time, thus they are associated with the development of dependency. Synthetic opiates have not been developed that have both, a strong analgesic effect and little or no potential for the development of dependency. Because endogenous endorphins have a similar euphoria-inducing capability as do opiates it is advantageous to use endogenous endorphins for inducing an elevated mood. However, because the administration of relatively large and prolonged doses of synthetic endorphins may be associated with the development of tolerance and dependency, they are not desirable long- term treatment agents.
- Mu receptors primarily mediate pain perception, but also induce euphoria when these receptors are bound by endorphin/ opiate compounds.
- the role of delta receptors in pain modulation is not clear, whereas they are likely more closely related to euphoria.
- Delta receptor agonists demonstrate anti-depressant activity in rats in the forced swim assay.
- delta-opioid receptors are involved in motivational activities. Their preferential involvement is through enkephalin- controlled behavior. Broom, et al. (JpnJ. Pharmacol. 2002 Sep;90(l):l-6) demonstrate that the delta opiate receptor plays a significant role in depression.
- Methods of the present invention using mu and/or delta receptor antagonists as ligands may be used to address undesirable mental or neurological conditions in patients.
- the methods of the present embodiment of the invention may be used to address any of the above-listed conditions.
- the methods according to the present embodiment of the invention may also be used as an adjunct treatment for cancer.
- Methods of the present invention using mu and/or delta receptor antagonists may be used to address pain that is anticipated to occur in the future. For example, if a patient is scheduled for elective surgery in, e.g., one month then the method of the present invention can be practiced with a mu and/or delta opiate receptor, using high night-time dosing for the intervening pre-operative period of time. After surgery the patient will have an enhanced response to pain due to the up-regulated endogenous endorphin system. In addition, the patient will require lower overall doses of narcotic pain medications post ⁇ operatively due to enhanced sensitivity of mu and/or delta opiate receptors. The method would likely best interrupted immediately after surgery so that post-operative pain would not increase due to the direct effects of receptor antagonism. It could be restarted in a few days or so, once the pain had subsided, in order to maintain the counteradaptive response.
- naloxone patch 200 mg, which is formulated to be rapidly absorbed over 6-8 hours as described above, on a nightly basis.
- diazepam 1-5 mg
- the naloxone is increased to 400 mg on a nightly basis.
- the anxiolytic agent is used if needed.
- the naloxone is increased to 600-800 mg on a nightly basis.
- naloxone On the night of surgery and for several nights in the peri-operative period no naloxone is given.
- the patient is given only standard post-operative pain medications such as morphine and codeine.
- the doses of these substances are significantly reduced compared to the average individual undergoing this type of surgery, due to the up regulation of this patient's endorphin system.
- the same patient is given a specific mu receptor antagonist along with the increasing dose of naloxone, in order to enhance the up regulation of pain-modulating mu receptors.
- the methods of the invention may be used with mu and/or delta antagonists to elevate a patient's mood in the treatment of depression and related conditions.
- non-specific opiate receptor antagonists e.g., naloxone
- mu opiate receptor antagonists could be used, especially when chronic pain is associated with the depressed mood.
- the maximal can stay for a long period of time at this 2000 mg total dose. Or it can continue to increase to 2,500, or 3,000 or 4,000mg over the ensuing year or more.
- the maximal dose comes to a plateau once there is a good clinical response or once the side effects become too great or if there is an elevation of liver function enzymes on a blood test.
- the maximum tolerable dose is then given for an extended period of time for maintenance therapy. If and when therapy is stopped the patient is carefully monitored for any signs of recurrence of the mood disorder.
- a delta opiate receptor antagonist along with the naloxone after the first 6 weeks to 3 months of treatment.
- the naloxone dose may continue to be increased or it may level off earlier when combined with the delta antagonist.
- a non-peptide delta opiate receptor antagonist such as naltrindole, natriben, or one of the agents discussed above, could be used.
- a peptide delta antagonist such as ICI-154,129 or ICI-174,864 peptide, could also be used.
- the starting dose for naltrindole is larger than that for naloxone. It may be as high as 10 mg/kg/administration.
- Naltrindole may be given as a transdermal compound or using any other effective formulation.
- the main consideration is the dosing for people with significant depression who may be at risk for suicide if the initial doses are too large.
- people with clinical depression because they are suicidal risks, should either not be treated or treated at an in-patient hospital or appropriate institution in order to better monitor the patient.
- These patients are dosed at relatively lower doses at the beginning of treatment and that the increase in dose is done at a slower rate.
- treatment may need to be started with a loading of only 10 mg of naloxone, with 10 or 20 mg to be absorbed over the ensuing 6 hours, for a total starting dose of 30 mg.
- the increase in dose after 2 weeks is more gradual than for the example above. At 2 weeks one would give 20 mg as a loading dose and 20-40 mg over the ensuing 6 hours. This gradual increase is continued for as many months as is needed to obtain a maximal clinical response.
- the neurotransmitter system is the dynorphin system, which includes dynorphins as neurotransmitters.
- Dynorphins are a class of endorphin compounds that bind preferentially to kappa receptors. Dynorphins generally have the opposite effect from the endorphins; their binding to kappa receptors is associated with a worsening of mood.
- the type of receptor is kappa receptors, which are positively linked to undesirable mental and neurological conditions. Kappa receptors are associated primarily with dysphoria when stimulated.
- the ligand is a kappa receptor agonist, and the counteradaptation causes a down-regulation of the dynorphin system.
- the counteradaptation may be, for example, a decrease in the biosynthesis or release of dynorphins at receptor terminals and/or by the pituitary gland; a decrease in the number of the receptors and/or dynorphin binding sites on the receptors; a decrease in the sensitivity of the receptors to binding by mu and/or delta receptor agonists and/or dynorphins; or a combination thereof.
- the counteradaptation may also up-regulate D2 (dopamine) receptors, which are negatively linked to depression.
- a variety of kappa receptor agonists may be used in the present invention.
- the kappa receptor agonist may be a peptide-based agonist, such as dynorphin [Dynorphin [Al-17], H-TYR-GLY-GLY-PHE-LEU-ARG-ARG-ILE ⁇ -ARG-PRO-LYS- LEU-LYS-TRP-ASP-ASN-GLN-OH] and all active peptide fragments and analogues thereof or a pharmaceutically acceptable salt, or carrier thereof.
- the kappa receptor agonist may be the active C-terminal fragment of dynorphin A(I -8), or a pharmaceutically accepted salt or carrier thereof.
- the kappa receptor agonist may also be non-peptidic.
- the kappa receptor agonist may be a nonbenzomorphan; enadoline; PDl 17302; CAM569; PD123497; GR 89,696; U69,593; TRK-820; trans-3,4-dichloro-N-methyl-N-[l-(l- pyrrolidinyl)cyclohexyl]benzene-acetamide; asimadoline (EMD-61753); benzeneacetamide; thiomorpholine; piperidine; benzo[b]thiophene-4-acetamide; trans-(+/- )-(PD-l 17302); 4-benzofuranacetamide (PD-129190); 2,6-methano-3-bezazocin-8-ol (MR- 1268); morphinan-3-ol (KT-90); GR-45809; 1-piperazinecarboxylic
- the kappa receptor agonist may be U50,488 (trans-3,4-dichloro-N-[2-(l- pyrrolidinyl) cyclohexyl] benzeacetamide) and spiradoline (U62,066E).
- Enadoline and PDl 17302 ⁇ Enadoline [(5i?)-5ct, 7x, 8 ⁇ )-N-methyl-N-[7-(l-pyrrolidinyl)-l-oxzspiro [4,5] dec-8-yl] -4-benzofuranacetamide monohydrochloride], PDl 17302 [( ⁇ )-tra ⁇ «-N-methyl-N- [2-( 1 -pyrrolidinyl)-cyclohexyl]benzo[b]thiophene-4-acetamide monohydrochloride] and their respective (+)-isomers (CAM569 andPD123497) (Parke-Davis Research Unit, Cambridge, UK) ⁇ are highly selective arylacetamide kappa opioids.
- GR89,696 (4-[(3,4- dichlorophenyl) acetyl] -3-(l-pyrrolidinylmethyl) -1-piperazinecarboxylic acid methyl ester fumarate) is a prototypical arylacetamide developed from the structure of U50,488H. It has high efficacy as a Ki agonist.
- U69,593 [ (5 alpha, 7 alpha, 8 beta)-(+)-N-methyl-N-(7-(l- pyrrolidinyl)- l-oxaspiro(4,5)dec-8-yl)benzeneacetamide ] is also a kappa agonist with Ki selectivity.
- TRK-820 ((-)-17-cyclopropylmethyl-3, 14b-dihydroxy-4,5a-epoxy-6b-[N- methyl-trans-3-(3-furyl) acrylamide] morphinan hydrochloride) (Toray Industries, Inc. Japan) is a potent kappa agonist with pharmacological properties different from those produced by Ki receptor agonists.
- Tifiuadom is a benzodiazepine kappa agonist (Sandoz, Inc., Princeton, NJ.)- US 4,758,562 also describes the kappa agonist: trans-3,4-dichloro- N-methyl-N-[l-(l-pyrrolidinyl)cyclohexyl]benzeneacetamide.
- Kappa receptor agonists are also described in U.S. Patents 5,051,428;
- the initial dosage of the kappa receptor agonist is desirably high enough to induce a counteradaptive effect, but not so high as to cause the patient intolerable direct effects.
- the initial dosage of the kappa receptor agonist may be equivalent to between 0.0005 and 0.05 mg/kg/administration of dynorphin; between 5 and 700 mg/administration of enadoline; between 1 and 500 ⁇ g/administration of FE 20665; between 0.5 and 100 ⁇ g/administration; between 0.01 and 1 mg/kg/administration of U69,593; between 0.05 and 5 mg/kg/administration of TRK 820; between 0.01 and 1 mg/kg/administration U 50 488 or between 0.01 and 1 mg/kg/administration of PD 117302.
- the initial dosage of the kappa receptor agonist is equivalent to between 0.005 and 0.02 mg/kg/administration of dynorphin; between 100 and 500 mg/administration of enadoline; between 3 and 100 ⁇ g/administration of FE 20665; between 1 and 80 ⁇ g/administration of FE 20666; between 0.1 and 0.7 mg/kg/administration of U69,593; between 0.5 and 3 mg/kg/administration of TRK 820; between 0.5 and 7 mg/kg/administration U 50 488 or between 0.1 and 0.7 mg/kg/administration of PD 117302.
- the kappa receptor agonist is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- Salvinorin A is a neoclerodane diterpene compound, which is a very powerful hallucinogen that has recently been found to have kappa agonist activity. It represents the only known non-nitrogenous kappa agonist compound. It is the main active ingredient of the plant S. divinorum (Diviner's sage), a rare member of the mint family. It has been used for many centuries by the Mazatec people of Oaxaca, Mexico in traditional spiritual practices.
- the initial dose of Salvinorin A is desirably between 5 and 50 ug/administration, and the maximum dose is desirably 5000 ug/administration.
- the Salvornin A may be administered transmucosally, or as a slow-release formulation, desirably over a period between two and six hours in duration.
- it may be desirable to administer both a peptidic kappa receptor agonist and a non-peptidic kappa receptor agonist.
- the two types of agonist may be administered substantially simultaneously, or sequentially.
- Peptidic kappa receptor agonists may be administered, for example, intravenously, transdermally, or transmucosally, as described above with respect to other peptidic ligands. As described above with respect to naloxone, it may be desirable to use transmucosal administration (to achieve a high level of ligand-receptor binding quickly) along with transdermal administration (to provide extended ligand-receptor binding).
- the body develops a tolerance to anti-opiates about eight days after first administration, it may be desirable to increase the dosage of the kappa receptor agonist with time. For example, it may be desirable to increase the dosage with a period of between a week and two weeks.
- the initial dose of Salvinorum A is low in order to decrease potential side effects.
- a dose between 5 ⁇ g-50 ⁇ g is the starting dose. After 2- 4 weeks this is increased by a certain percent. The increase could be as small as 5-10% or 50-100% or more. Generally, a doubling of the initial dose is recommended.
- the individual is given 20-100 ⁇ g of Salvinorum A. This increase in dose is continued every two, four, six or eight weeks. It may also continue to increase on a quarterly, semiannual or annual basis. Doses of 200 ⁇ g may produce increasing dysphoric effects. This occurs with acute administration. With chronic gradual increase in dose the side effects would be gradually muted. With chronic gradual increase in dosing the maximum dose of Salvinorum A is 1000 ⁇ g to 5000 ⁇ g or more.
- a rectal suppository transmucosal formulation
- the initial dose is high enough in order to induce a counteradaptive response, but low enough to minimize dysphoric effects of agonist-receptor binding.
- Enadoline is a non-peptidic kappa receptor agonist. It has pharmaceutical activity when taken as an oral dose at 1-10 mg/kg.
- an initial dose of 100-200 mg is administered daily just prior to the patient's going to bed. After 2-4 weeks the dose is increase to 200-500 mg. After another 2-4 weeks the dose is increased to 500-1000 mg. After another two, four, eight weeks or more, it is increased to 1500-2000 mg. The dose is increased as long as side effects do not become uncontrollable.
- a kappa receptor antagonist is not administered during the first time period associated with each administration. In certain embodiments of the invention, however, a kappa receptor antagonist is administered during one or more of the second time periods.
- Representative kappa receptor antagonists include the compounds described in U.S. Patent no. 5,025,018; 5,922,887; and 6,284,769.
- a suitable dosage includes 0.1 to 10 mg/administration per day; for U.S. Patent no. 6,284,769, suitable dosages include 0.1 to 500 mg/administration.
- the dynorphin neurotransmitter system and its kappa receptors are positively linked to a wide variety of undesirable mental and neurological conditions.
- undesirable mental and neurological conditions include pain, mood disorders, eating disorders, anxiety disorders, motivational problem, substance abuse disorders, insufficient motivation or performance, pain that is expected to occur in the future (e.g., due to a future operation or future physical exertion), chronic pain syndromes, acute pain, fibromyalgia, chronic fatigue syndrome, chronic back pain, chronic headaches, shingles, reflex sympathetic dystrophy, neuropathy, inflammatory pain, chronic cancer pain, major depressive disorders, post traumatic depression, temporary depressed mood, manic-depressive disorders, dysthymic disorders, generalized mood disorders, anhedonia, non-organic sexual dysfunction, overeating, obesity, anorexia, bulimia, generalized anxiety state, panic disorders, Tourette's Syndrome, hysteria sleep disorders, breathing-related sleep disorders, lack of motivation due to learning or memory problems, abuse of substances such as narcotics
- the neurotransmitter system is the serotonin system which includes serotonin as a neurotransmitter.
- Serotonin is a monoamine neurotransmitter.
- Low serotonin levels are associated with depression.
- the counteradaptation causes an up-regulation of the serotonin system.
- serotonin receptors (at least 14) have been identified. The greatest concentration of serotonin (90%) are located in the gastrointestinal tract. Most of the remainder of the body's serotonin is found in platelets and the central nervous system (CNS). The effects of serotonin are noted in the cardiovascular system, the respiratory system and the intestines. Vasoconstriction is a typical response to serotonin.
- the function of serotonin is exerted upon its interaction with specific receptors.
- serotonin receptors have been cloned and are identified as 5HTi, 5HT 2 , 5HT 3 , 5HT 4 , 5HT 5 , 5HT 6 , and 5HT 7 .
- Within the 5HTi group there are subtypes 5HTi A , 5HTiB, 5HTID, 5HTiE, and 5HTi F .
- Most of these receptors are coupled to G-proteins that affect the activities of either adenylate cyclase or phospholipase Cg.
- the 5HT 3 class of receptors are ion channels
- 5HT 2A receptors mediate platelet aggregation and smooth muscle contraction.
- the 5HT 2 c receptors are suspected in control of food intake as mice lacking this gene become obese from increased food intake and are also subject to fatal seizures.
- the 5HT 3 receptors are present in the gastrointestinal tract and are related to vomiting. Also present in the gastrointestinal tract are 5HT 4 receptors where they function in secretion and peristalsis.
- the 5HT 6 and 5HT 7 receptors are distributed throughout the limbic system of the brain and the 5HT 6 receptors have high affinity for antidepressant drugs.
- the most common serotonin receptors that are associated with mood and depression are the 1 st and 2 nd ones, most especially the 5HT 1A receptors.
- serotonin neuron When a serotonin neuron is stimulated to fire, serotonin is released into the synapse. Some serotonin molecules cross the synapse and bind to the post-synaptic receptor, which then causes firing of the post-synaptic serotonin neuron. Binding of serotonin to the post-synaptic serotonin neuron causes its activation, which leads to a series of neural events that is associated with a generally good mood.
- serotonin When serotonin is released into the synaptic cleft only a portion of the serotonin actually binds to post-synaptic receptors. The majority of serotonin molecules are removed from the synapse by a reuptake mechanism. Some of this serotonin is degraded by monoamine oxidases, enzymes that degrade both serotonin and norepinephrine.
- the third target of serotonin molecules are the pre-synaptic auto-receptors.
- the pre-synaptic autoreceptors are inhibitory receptors.
- the pre-synaptic autoreceptors act in a feedback inhibition loop that functions as a control mechanism for neurotransmitter release.
- a feedback inhibition loop is a common manner by which the body controls the activation of neurons. When they are bound by sertonin, or an agonist, they inhibit the further release of sertonin into the synapse.
- Pre-synaptic autoreceptors are termed 5HT 1A and 5HT 1 B pre-synaptic autoreceptors.
- 5HT 1A autoreceptors inhibit the tonic release of serotonin.
- 5HT IB autoreceptors are thought to inhibit the evoked release and synthesis of serotonin.
- the type of receptor may be, for example, serotonin pre-synaptic autoreceptors such as 5HT 1A autoreceptors or 5HT 1B autoreceptors.
- the ligand is a serotonin pre-synaptic autoreceptor agonist, and the undesirable mental or neurological condition is positively linked to the receptors.
- the counteradaptation may be, for example, an increase in the biosynthesis and/or release of serotonin at the synaptic cleft; a decrease in the reuptake of serotonin; a decrease in the number of serotonin pre-synaptic autoreceptors; a decrease in the sensitivity of the serotonin pre-synaptic autoreceptors to serotonin and/or serotonin pre ⁇ synaptic autoreceptor agonists; an increase in the number of serotonin post-synaptic receptors; an increase in the sensitivity of the serotonin post-synaptic receptors to serotonin or serotonin post-synaptic receptor agonists; or a combination thereof.
- serotonin pre-synanptic autoreceptor agonists may be used in the methods of the present invention.
- the serotonin pre-synaptic autoreceptor agonist may be EMD-68843, buspirone, gepirone, ipsapirone, tandospirone, Lesopitron, zalospirone, MDL-73005EF, or BP-554.
- the initial dosage of the serotonin pre-synaptic autoreceptor agonist is desirably high enough to induce a counteradaptive effect, but not so high as to cause the patient intolerable direct effects.
- the initial dosage of the serotonin pre ⁇ synaptic autoreceptor agonist may be equivalent to between 1 and 400 mg/administration of EMD-68843, between 1 and 500 mg/administration buspirone, between 1 and 500 mg/administration lesopitron, between 1 and 500 mg/administration gepirone, between 5 and 500 mg tandospirone, or between 1 and 200 mg zalospirone.
- the initial dosage of the serotonin pre-synaptic autoreceptor agonist is equivalent to between 10 and 100 mg/administration of EMD-68843, between 10 and 100 mg/administration buspirone, between 10 and 200 mg/administration lesopitron, between 10 and 100 mg/administration gepirone, between 20 and 200 mg tandospirone, or between 10 and 100 mg zalospirone.
- a serotonin pre-synaptic autoreceptor antagonist is not administered during the first time period associated with each administration. In certain embodiments of the invention, however, a serotonin pre-synaptic autoreceptor antagonist is administered during one or more of the second time periods.
- Representative serotonin pre ⁇ synaptic autoreceptor 5HT IA agonists and antagonists include Elazonan, AR- A2 (AstraZeneca, London, UK); AZD-1134 [AstraZeneca, London, UK); Pindolol, as well as compounds described in US 6,462,048; 6,451,803; 6,627,627; 6,602,874; 6,277,852; and 6,166,020, incorporated by reference in their entirety.
- the type of receptor is serotonin post-synaptic receptors, such as are 5HT 1 receptors; 5HT 2 receptors; 5HT 3 receptors; 5HT 4 receptors; 5HTs receptors; 5HT 6 receptors; 5HT 7 receptors; or receptors of a subtype thereof.
- the ligand is a serotonin post-synaptic receptor antagonist, and the undesirable mental or neurological condition is negatively linked with the receptors.
- the counteradaptation may be an increase in the biosynthesis and/or release of serotonin at the synaptic cleft; a decrease in the reuptake of serotonin; an increase in the number of serotonin post-synaptic receptors; an increase in the sensitivity of the serotonin post ⁇ synaptic receptors to serotonin and/or serotonin post-synaptic receptor agonists; a decrease in the number of serotonin pre-synaptic autoreceptors; a decrease in the sensitivity of the serotonin pre-synaptic autoreceptors to serotonin and/or serotonin pre-synaptic autoreceptor agonists; or a combination thereof.
- the serotonin post-synaptic receptor antagonists may be (S)-WAY- 100135, WAY-100635, buspirone, gepirone, ipsapirone, tandospirone, Lesopitron, zalospirone, MDL-73005EF, or BP-554.
- an SSRI maybe administered either simultaneously or sequentially with the aforementioned serotonin modulating agents. This is advantageous as both SSRI and agonist pre-synaptic counteradaptive therapy result in a down regulation of the pre-synaptic receptors. The SSRI effect is thus magnified by such a counteradaptive effect.
- any down regulation of the post synaptic serotonin receptors that may occur with SSRI therapy is counterbalanced by post synaptic antagonist counteradaptive therapy.
- the initial dosage of the serotonin post-synaptic antagonist is desirably high enough to induce a counteradaptive effect, but not so high as to cause the patient intolerable direct effects.
- the initial dosage of the serotonin post-synaptic receptor antagonist is equivalent to between about 0.01 and 5 mg/kg/administration of WAY-100635.
- the initial dosage of the serotonin post-synaptic receptor antagonist is equivalent to between about 0.025 and 1 mg/kg/administration of WAY- 100635.
- the serotonin post-synaptic receptor antagonist may be administered in combination with a serotonin pre-synaptic autoreceptor agonist, such as those described above. Further, when conventional anti-depressant agents that bind at the serotonin post ⁇ synaptic receptors are given in combination with a serotonin pre-synaptic autoreceptor agonist, its efficacy can be greatly increased because the serotonin post-synaptic receptors have increased in number and/sensitivity through the counteradaptation.
- the serotonin post ⁇ synaptic antagonist itself is also a serotonin pre-synaptic autoreceptor agonist. It may also be desirable to administer a norepinephrine pre-synaptic alpha-2 adrenergic receptor agonist and/or a norepinephrine post-synaptic adrenergic receptor antagonist (as described below) in combination with the serotonin post-synaptic antagonist or serotonin pre-synaptic autoreceptor agonist.
- a serotonin post-synaptic receptor agonist is not administered during the first time period associated with each administration. In certain embodiments of the invention, however, a serotonin post-synaptic receptor agonist is administered during one or more of the second time periods.
- Representative serotonin post-synaptic receptor agonists include BIMT 17 (l-[2-[4-(3-trifluoromethyI phenyl) piperazin-1-yl] ethyl] benzimidazol- [lH]-2-one), dose: 1- 10 mg/kg (i.v. or transdermal, SQ, etc.).
- a suitable dosage range includes 1 to 10 mg/kg/administration of BIMT 17 (via iv, transdermal, or SQ).
- Serotonin post-synaptic receptors are negatively linked, and serotonin pre ⁇ synaptic autoreceptors are positively linked to a wide variety of undesirable mental and neurological conditions.
- Examples of such conditions include pain, mood disorders, eating disorders, anxiety disorders, obsessive-compulsive disorders, motivational problem, substance abuse disorders, insufficient motivation or performance, pain that is expected to occur in the future (e.g., due to a future operation or future physical exertion), chronic pain syndromes, acute pain, fibromyalgia, chronic fatigue syndrome, chronic back pain, chronic headaches, shingles, reflex sympathetic dystrophy, neuropathy, inflammatory pain, chronic cancer pain, major depressive disorders, post traumatic depression, temporary depressed mood, manic-depressive disorders, dysthymic disorders, generalized mood disorders, anhedonia, non-organic sexual dysfunction, overeating, obesity, anorexia, bulimia, generalized anxiety state, panic disorders, Tourette's Syndrome, hysteria sleep disorders, breathing-
- the neurotransmitter system is the norepinephrine system which includes norepinephrine as a neurotransmitter, and the counteradaptation causes an up-regulation of the norepinephine system.
- Norepinephrine is a catecholamine that, along with epinephrine, acts as a neurotransmitter in the central nervous system.
- adrenoreceptors There are two types of adrenoreceptors, alpha and beta. There are in addition, at least ten different subtypes of adrenoreceptors.
- Norepinephrine generally is more potent at sites where sympathetic neurotransmission is excitatory and is mediated through alpha receptors.
- Alpha receptors have two main subclasses, alphal and alpha2.
- Norepinephrine acts a neuromodulator in the central nervous system.
- the central nervous system actions of NE are most notable when it modulates excitatory or inhibitory inputs, rather than its effects on the activity of post-synaptic targets, in the absence of other inputs.
- Norepinephrine transmission and control is similar to that for serotonin.
- a reuptake mechanism is present that removes the majority of norepinephrine after its release into the noradrenergic synapse.
- the type of receptor may be, for example, norepinephrine pre-synaptic alpha-2 adrenergic receptors.
- the ligand is a norepinephrine pre-synaptic alpha-2 adrenergic receptor agonist, and the undesirable mental or neurological condition is positively linked to the receptors.
- the counteradaptation may be an increase in the biosynthesis and/or release of norepinephrine at the synaptic cleft; a decrease in reuptake of norepinephrine; a decrease in the number of norepinephrine pre-synaptic alpha-2 adrenergic receptors; a decrease in the sensitivity of the norepinephrine pre-synaptic alpha-2 adrenergic receptors to norepinephrine and/or norepinephrine pre-synaptic alpha-2 adrenergic receptor agonists; an increase in the number of norepinephrine post-synaptic adrenergic receptors; an increase in the sensitivity of the norepinephrine post-synaptic adrenergic receptors to norepinephrine and/or norepinephrine post-synaptic adrenergic receptor agonists; or a
- norepinephrine pre-synaptic alpha-2 adrenergic receptor agonists may be used as the norepinephrine pre-synaptic alpha-2 adrenergic receptor agonists in the methods of the present invention.
- the norepinephrine pre-synaptic alpha-2 adrenergic receptor agonist may be clonidine, guanfacine, lofexidine, detomidine, dexmedetomidine, mivazerol, or alpha- methylnoradreniline.
- the initial dosage of the norepinephrine pre-synaptic alpha-2 adrenergic receptor agonist is desirably high enough to induce a counteradaptive effect, but not so high as to cause the patient intolerable direct effects.
- the initial dosage may be equivalent to between 0.1 and 10 ⁇ g/kg/administration of clonidine, between 0.01 and 10 mg/administration guanfacine, between 0.01 and 1 mg/administration lofexidine, between 1 and 100 ⁇ g/kg/administration detomidine, between 0.05 and 5 ⁇ g/kg/administration dexmedetomidine, between 0.05 and 10 ⁇ g/kg/administration mivazerol, or between 5 and 500 ng/kg/administration of alpha-methylnoradreniline.
- the initial dosage is equivalent to between 0.1 and 0.5 mg/administration of clonidine, between 0.1 and 5 mg/administration guanfacine, between 0.05 and 0.5 mg/administration lofexidine, between 10 and 80 ⁇ g/kg/administration detomidine, between 0.1 and 3 ⁇ g/kg/administration dexmedetomidine, between 0.5 and 5 ⁇ g/kg/administration of mivazerol, or between 10 and 100 ng/kg/administration of alpha- methylnoradreniline.
- a norepinephrine pre-synaptic alpha-2 adrenergic receptor antagonist is not administered during the first time period associated with each administration.
- an norepinephrine pre ⁇ synaptic alpha-2 adrenergic receptor antagonist is administered during one or more of the second time periods.
- a suitable non-limiting example of a pre and postsynaptic A2AR antagonist includes mirtazapine.
- the type of receptor is norepinephrine post-synaptic adrenergic receptors, such as alpha receptors, beta receptors, or receptors of a subtype thereof.
- the ligand is a norepinephrine post ⁇ synaptic adrenergic receptor antagonist, and the undesirable mental or neurological condition is negatively linked to the norepinephrine post-synaptic adrenergic receptors.
- the counteradaptation may be an increase in the biosynthesis or release of norepinephrine at the synaptic cleft; a decrease in the reuptake of norepinephrine; an increase in the number of norepinephrine post-synaptic adrenergic receptors; an increase in the sensitivity of the norepinephrine post-synaptic adrenergic receptors to norepinephrine and/or norepinephrine post-synaptic adrenergic receptor agonists; a decrease in the number of norepinephrine pre-synaptic alpha-2 adrenergic receptors; a decrease in the sensitivity of the norepinephrine pre-synaptic alpha-2 adrenergic receptors to norepinephrine and/or norepinephrine pre-synaptic alpha-2 adrenergic receptor agonists; or a combination
- the norepinephrine post-synaptic adrenergic receptor antagonist may be idazoxan, SKF 104078, or SKF 104856.
- the initial dosage of the norepinephrine post-synaptic adrenergic receptor antagonist is desirably high enough to induce a counteradaptive effect, but not so high as to cause the patient intolerable direct effects.
- the initial dosage may be equivalent to between 0.5 and 100 mg/administration of idazoxan.
- the initial dosage is equivalent to between 5 and 50 mg/administration of idazoxan.
- a norepinephrine post-synaptic adrenergic receptor agonist is not administered during the first time period associated with each administration. In certain embodiments of the invention, however, a norepinephrine post-synaptic adrenergic receptor agonist is administered during one or more of the second time periods.
- the norepinephrine post-synaptic adrenergic receptor antagonist may be administered in combination with a norepinephrine pre-synaptic alpha-2 adrenergic receptor agonist, such as those described above.
- a norepinephrine pre-synaptic alpha-2 adrenergic receptor agonist such as those described above.
- conventional anti ⁇ depressant agents that bind at the norepinephrine post-synaptic adrenergic receptors are given in combination with a norepinephrine pre-synaptic alpha-2 adrenergic receptor agonist, its efficacy can be greatly increased because the norepinephrine post-synaptic adrenergic receptors have increased in number and/sensitivity through the counteradaptation.
- the norepinephrine post ⁇ synaptic adrenergic receptor antagonist itself is also an norepinephrine pre-synaptic alpha-2 adrenergic receptor agonist. It may also be desirable to administer a serotonin post ⁇ synaptic antagonist and/or a serotonin pre-synaptic autoreceptor agonist (as described above) in combination with the norepinephrine pre-synaptic alpha-2 adrenergic receptor agonist or norepinephrine post-synaptic adrenergic receptor antagonist.
- Norepinephrine post-synaptic adrenergic receptors are negatively linked, and norepinephrine pre-synaptic alpha-2 adrenergic receptors are positively linked to a wide variety of undesirable mental and neurological conditions.
- Examples of such conditions include pain, mood disorders, eating disorders, anxiety disorders, obsessive- compulsive disorders, motivational problem, substance abuse disorders, insufficient motivation or performance, pain that is expected to occur in the future (e.g., due to a future operation or future physical exertion), chronic pain syndromes, acute pain, fibromyalgia, chronic fatigue syndrome, chronic back pain, chronic headaches, shingles, reflex sympathetic dystrophy, neuropathy, inflammatory pain, chronic cancer pain, major depressive disorders, post traumatic depression, temporary depressed mood, manic- depressive disorders, dysthymic disorders, generalized mood disorders, anhedonia, non ⁇ organic sexual dysfunction, overeating, obesity, anorexia, bulimia, generalized anxiety state, panic disorders, Tourette's Syndrome, hysteria sleep disorders, breathing-related sleep disorders, lack of motivation due to learning or memory problems, abuse of substances such as narcotics, alcohol, nicotine, stimulants, anxiolytics, CNS depressants, hallucinogens and
- ligands for different receptors can be administered in combination either sequentially or simultaneously.
- repeated administration of a mu and/or delta opiate antagonist can be followed by (or performed simultaneously with) repeated administration of an SP receptor antagonist.
- an NRI maybe administered either simultaneously or sequentially with the aforementioned NE modulating agents.
- Simultaneous or sequential co-administration is desirable as opiate and SP systems overlap with both serotonin and NE systems. Any increased sensitivity of the opiate and/ or SP systems also has an effect on serotonin and NE systems.
- the enhanced sensitivity of the serotonin or NE systems that is a result of counteradaptive therapy generates an enhanced response to either SSRI or NRI therapy.
- Bilkei-Gorzo et al., "Diminished Anxiety- and Depression-Related Behaviors in Mice with Selective Deletion of the Tacl Gene" J Neurosci. 2002 Nov 15; 22(22): 10046-52.
- Bodkin, JA "Buprenorphine treatment of refractory depression” J Clin Psychopharmacol. 1995 Feb; 15(1): 49-57.
- Boehm S "Presynaptic alpha2-adrenoceptors control excitatory, but not inhibitory, transmission at rat hippocampal synapses” J Physiol (Lond). 1999 Sep 1; 519(Pt 2): 439- 449.
- Fava, GA "Can long-term treatment with antidepressant drugs worsen the course of depression?" J Clin Psychiatry 2003 Feb; 64(2): 123-33. Fawcett, J, et al., "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression” J Affect Disord. 1998 Dec; 51(3): 267-85.
- Flaumenhaft, R "Platelets feel your pain” Blood. 2004; 104(4): 913.
- Haddjeri, N, et al. "Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5- hydroxytryptamine system in the rat brian.” Pharmacol Exp Ther. 1996 May 1 ; 277(2): 861-871.
- Haddjeri, H, et al. "Long-Term Antidepressant Treatments Result in a Tonic Activation of Forebrain 5-HT 1A Receptors" J Neuroscience. 1998 Dec 1; 18(23): 10150-10156.
- Hay, D "Tachykinin Antagonists” from New Drugs for Asthma, Allergy and COPD. Hansel TT, Barnes PJ (eds): Prog Respir Res. Basel, Karger, 2001, vol. 31: 145-150.
- Minabe, Y, et al. "Effect of the acute and chronic administration of the selective neurokinin2 receptor antagonist SR 48968 on midbrain dopamine neurons in the rat: An in vivo extracellular single cell study" Synapse. 1997; 25: 196-204.
- Morris, BJ, et al. "Antagonist-induced opioid receptor up-regulation. II. Regionally specific modulation of mu, delta and kappa binding sites in rat brain revealed by quantitative autoradiography" J Pharmacol Exp Ther. 1988 Nov 1; 247(2): 729-736.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005286733A AU2005286733B2 (en) | 2004-09-23 | 2005-09-23 | Methods for regulating neurotransmitter systems by inducing counteradaptations |
JP2007533610A JP2008514612A (en) | 2004-09-23 | 2005-09-23 | Methods of modulating neurotransmitter systems by inducing counter adaptation |
CA002580694A CA2580694A1 (en) | 2004-09-23 | 2005-09-23 | Methods for regulating neurotransmitter systems by inducing counteradaptations |
EP05800810A EP1809104A4 (en) | 2004-09-23 | 2005-09-23 | Methods for regulating neurotransmitter systems by inducing counteradaptations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61215504P | 2004-09-23 | 2004-09-23 | |
US60/612,155 | 2004-09-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006034343A2 true WO2006034343A2 (en) | 2006-03-30 |
WO2006034343A3 WO2006034343A3 (en) | 2006-10-05 |
Family
ID=36090649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/033826 WO2006034343A2 (en) | 2004-09-23 | 2005-09-23 | methods for regulating neurotransmitter systems by inducing counteradaptationS |
Country Status (7)
Country | Link |
---|---|
US (3) | US20060069086A1 (en) |
EP (1) | EP1809104A4 (en) |
JP (2) | JP2008514612A (en) |
CN (1) | CN101065014A (en) |
AU (1) | AU2005286733B2 (en) |
CA (1) | CA2580694A1 (en) |
WO (1) | WO2006034343A2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007131154A2 (en) * | 2006-05-04 | 2007-11-15 | Accelerated Technologies Corporation | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
EP2001495A2 (en) * | 2006-02-27 | 2008-12-17 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
AT505086B1 (en) * | 2007-04-02 | 2009-06-15 | Planta Naturstoffe Vertriebsge | PHARMACEUTICAL AGENT AGAINST JUCKREIZ AND JUCKREIZED PAIN |
US7829596B2 (en) | 1998-10-15 | 2010-11-09 | Imperial Innovations Limited | Methods of treatment |
US8138226B2 (en) | 2005-12-01 | 2012-03-20 | Auspex Pharmaceuticals | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
US8202525B2 (en) | 2009-12-22 | 2012-06-19 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
CN104955483A (en) * | 2013-01-30 | 2015-09-30 | 法莫斯医疗公司 | Treatments for depression and other diseases with a low dose agent |
US10421710B2 (en) | 2007-03-15 | 2019-09-24 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
US10772871B2 (en) | 2013-10-07 | 2020-09-15 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
US10874642B2 (en) | 2013-10-07 | 2020-12-29 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
US10987342B2 (en) | 2013-10-07 | 2021-04-27 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
US20040204862A1 (en) * | 2003-04-11 | 2004-10-14 | Wainer Irving W. | Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors |
RU2350327C2 (en) | 2003-04-29 | 2009-03-27 | Ориксиджен Серапьютикс, Инкорпорэйтд | Compounds causing weight loss |
DE602006014480D1 (en) * | 2005-09-08 | 2010-07-08 | Texcontor Ets | Lofexidine for intraspinal use |
BRPI0618918B8 (en) * | 2005-11-22 | 2021-05-25 | Nalpropion Pharmaceuticals Llc | use of a first compound and a second compound to treat a blood glucose condition |
BRPI0619806A2 (en) * | 2005-12-13 | 2011-10-18 | Biodelivery Sciences Int Inc | abuse resistant transmucosal drug delivery device |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
BRPI0714712B8 (en) | 2006-07-21 | 2021-05-25 | Biodelivery Sciences Int Inc | drug delivery device |
US7820689B2 (en) * | 2006-08-10 | 2010-10-26 | Hua-Lin Wu | Methods and compositions for preventing or treating cardiovascular disease |
RU2009116834A (en) * | 2006-11-09 | 2010-12-20 | Ориксиджен Терапьютикс, Инкорпорэйтд Сша/Сша (Us) | METHOD FOR ADMINISTRATION OF MEDICINES FOR REDUCING WEIGHT |
US8088786B2 (en) | 2006-11-09 | 2012-01-03 | Orexigen Therapeutics, Inc. | Layered pharmaceutical formulations |
GB0624282D0 (en) | 2006-12-05 | 2007-01-10 | Cavalla David | Treatment of cachexia |
FR2912058A1 (en) * | 2007-02-07 | 2008-08-08 | Sanofi Aventis Sa | Treatment or prevention of sexual dysfunction, e.g. lack of sexual desire or erectile dysfunction, uses neurokinin A NK2 receptor antagonist, e.g. sareductant |
CA2685861A1 (en) * | 2007-05-10 | 2008-11-20 | Amr Technology, Inc. | Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
AU2008251557B2 (en) * | 2007-05-10 | 2012-12-06 | Albany Molecular Research, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
CA2691220C (en) * | 2007-06-22 | 2015-05-05 | Toray Industries, Inc. | Remedy or preventive for integration dysfunction syndrome |
US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
JP2011500686A (en) * | 2007-10-18 | 2011-01-06 | アイコ バイオテクノロジー | Combined analgesics using opioids and neutral antagonists |
US8691768B2 (en) * | 2008-05-01 | 2014-04-08 | The Regents Of The University Of California | Methods of determining delta opioid receptor subtypes |
EP2303025A4 (en) | 2008-05-30 | 2012-07-04 | Orexigen Therapeutics Inc | Methods for treating visceral fat conditions |
DK2379066T3 (en) * | 2008-09-16 | 2014-06-30 | Imunek Farma Ilaç Sanayi Ve Ticaret A S | APPLICATION OF OPIOID ANTAGONISTS FOR THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF RETAINED DEGENERY DISEASES |
SG10201402346UA (en) * | 2009-05-19 | 2014-10-30 | Vivia Biotech Sl | Methods for providing personalized medicine tests ex vivo for hematological neoplasms |
ES2762113T3 (en) * | 2010-01-11 | 2020-05-22 | Nalpropion Pharmaceuticals Inc | Methods of providing weight loss therapy in patients with major depression |
TR201002473A2 (en) | 2010-03-31 | 2011-09-21 | Mustafa Nevzat �La� Sanay�� A.�. | A method of treating herpes zoster disease using an opiate receptor antagonist. |
BR112014003651B1 (en) | 2011-08-18 | 2022-03-29 | Biodelivery Sciences International, Inc | Misuse-resistant mucoadhesive devices for the release of buprenorphine |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
EP4104824A1 (en) | 2012-06-06 | 2022-12-21 | Nalpropion Pharmaceuticals LLC | Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk |
US8974365B2 (en) | 2012-11-25 | 2015-03-10 | Steven Richard Devore Best | Treatment of thalamocortical dysrhythmia |
MA41689A (en) * | 2014-10-15 | 2017-08-22 | Bioxcel Corp | PREVENTION OR TREATMENT OF SLEEP DISORDERS WITH A DEXMEDETOMIDINE FORMULATION |
CN106008672B (en) * | 2016-06-20 | 2020-06-16 | 郑州大学 | Synthetic peptide NK3R-A2 based on NK3 receptor and application thereof |
CN106008673B (en) * | 2016-06-20 | 2020-06-16 | 郑州大学 | Synthetic peptide NK3R-A1 based on NK3 receptor and application thereof |
BR112019013503A2 (en) | 2016-12-31 | 2020-01-07 | Bioxcel Therapeutics, Inc. | USE OF SUBLINGUAL DEXMEDETOMIDINE TO TREAT AGITATION |
WO2019171333A1 (en) * | 2018-03-08 | 2019-09-12 | Victoria Link Ltd | Treatment of demyelinating diseases |
AU2019295699A1 (en) | 2018-06-27 | 2021-01-28 | Arx, Llc | Film formulations containing dexmedetomidine and methods of producing them |
AU2020239245A1 (en) * | 2019-03-14 | 2021-11-11 | Lactocore, Inc. | Synthetic neuromodulatory peptides |
MX2022000709A (en) | 2019-07-19 | 2022-05-19 | Bioxcel Therapeutics Inc | Non-sedating dexmedetomidine treatment regimens. |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3980641A (en) * | 1975-07-31 | 1976-09-14 | Bristol-Myers Company | Process for the preparation of 14-hydroxymorphinans |
US4081434A (en) * | 1977-03-11 | 1978-03-28 | Hoffmann-La Roche Inc. | Novel analogs of β-endorphin |
US4217353A (en) * | 1978-05-19 | 1980-08-12 | E. I. Du Pont De Nemours And Company | Method for inducing anorexia |
US4272540A (en) * | 1979-04-24 | 1981-06-09 | Sisa, Incorporated | 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them |
US4377595A (en) * | 1979-08-13 | 1983-03-22 | Massachusetts Institute Of Technology | Process for reducing depression |
US4322426A (en) * | 1980-04-28 | 1982-03-30 | E. I. Du Pont De Nemours And Company | 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists |
DE3271003D1 (en) * | 1981-09-15 | 1986-06-12 | Ici Plc | Amino-substituted tetralins and related homocyclic compounds |
ZA827000B (en) * | 1981-09-25 | 1984-05-30 | Wellcome Found | Pharmaceutical amides,and preparation,formulations and use thereof |
US4537878A (en) * | 1981-10-05 | 1985-08-27 | Tni Pharmaceuticals, Inc. | Process for using endogenous enkephalins and endorphins to stimulate the immune system |
US4757049A (en) * | 1981-10-05 | 1988-07-12 | Tni Pharmaceuticals, Inc. | Process for using endogenous enkephalins and endorphins to stimulate the immune system of patients with aids |
US4801614A (en) * | 1981-10-05 | 1989-01-31 | Tni Pharmaceuticals, Inc. | Process for using endogenous enkephalins and endorphins to inhibit growth of tumerous cells |
US4462941A (en) * | 1982-06-10 | 1984-07-31 | The Regents Of The University Of California | Dynorphin amide analogs |
US4468383A (en) * | 1982-09-29 | 1984-08-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service | Dimeric enkephalins |
US4567185A (en) * | 1983-05-13 | 1986-01-28 | Key Pharmaceuticals, Inc. | Endorphin blockage |
US4518711A (en) * | 1983-05-16 | 1985-05-21 | Gibson-Stephens Institute | Conformationally constrained cyclic enkephalin analogs with delta receptor specificity |
US4535157A (en) * | 1983-11-01 | 1985-08-13 | Key Pharmaceuticals, Inc. | Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone |
US4684624A (en) * | 1983-12-22 | 1987-08-04 | Yoshio Hosobuchi | Method of treating cerebral ischemia |
IT1206339B (en) * | 1984-01-13 | 1989-04-14 | Anic Spa | HEXAPEPTID RETRO INVERTED ANALOGS C-TERMINALS OF THE SUBSTANCE P. |
US4689332A (en) * | 1984-04-09 | 1987-08-25 | Research Corporation | Growth regulation and related applications of opioid antagonists |
US5266574A (en) * | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
US4668685A (en) * | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
US4684620A (en) * | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
US4600718A (en) * | 1984-09-18 | 1986-07-15 | Huebner Hans F | Method of treating weight loss disorders |
US4680283A (en) * | 1984-09-26 | 1987-07-14 | Merck & Co., Inc. | Analogs of substance P and eledoisin |
US4573995A (en) * | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
US4910152A (en) * | 1985-01-31 | 1990-03-20 | Meyers Vera K | Method for binding opioid receptors |
US4761429A (en) * | 1985-07-22 | 1988-08-02 | Kenneth Blum | Enkephalinase and endorphinase inhibitors as anti-craving compositions |
US4990617A (en) * | 1985-12-02 | 1991-02-05 | E. I. Du Pont De Nemours And Company | N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans and derivatives |
US4758562A (en) * | 1985-12-18 | 1988-07-19 | Temple University Of The Commonwealth System Of Higher Education | Method for inducing hypothermia and/or poikilothermia |
US4910153A (en) * | 1986-02-18 | 1990-03-20 | Solarex Corporation | Deposition feedstock and dopant materials useful in the fabrication of hydrogenated amorphous silicon alloys for photovoltaic devices and other semiconductor devices |
US4673679A (en) * | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
US4767764A (en) * | 1986-05-27 | 1988-08-30 | E. I. Du Pont De Nemours And Company | Alkoxyalkyl and alkylmercaptoalkyl substituted bridged benzofuroisoquinolines having opioid antagonist and/or appetite-controlling properties |
US5013739A (en) * | 1986-10-07 | 1991-05-07 | Bernard Bihari | Method of treating chronic fatigue syndrome using an opiate receptor antagonist |
US6586443B1 (en) * | 1986-10-07 | 2003-07-01 | Bernard Bihari | Method of treating multiple sclerosis |
US5246941A (en) * | 1986-12-17 | 1993-09-21 | Glaxo Group Limited | Method for the treatment of depression |
US4839465A (en) * | 1987-01-20 | 1989-06-13 | Sterling Drug Inc. | Di-(D-tryptophyl and/or tetrahydropyridoindolylcarbonyl)-containing peptide amides and process for preparation thereof |
US5025018A (en) * | 1987-06-05 | 1991-06-18 | Medicis Corporation | Central nervous system injury treatment with opiate-receptor antagonist |
CA1335227C (en) * | 1987-06-22 | 1995-04-11 | Wylie W. Vale, Jr. | Crf analog conjugates |
US4816586A (en) * | 1987-07-29 | 1989-03-28 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
US5410019A (en) * | 1987-09-24 | 1995-04-25 | The Administrators Of The Tulane-Educational Fund | Therapeutic peptides |
US5137673A (en) * | 1987-11-17 | 1992-08-11 | Monsanto Company | Process for forming plasticized polyvinyl butyral sheet |
US4912114A (en) * | 1988-03-18 | 1990-03-27 | Sandoz Ltd. | Morphinan derivatives |
KR910001937Y1 (en) * | 1988-05-18 | 1991-03-30 | 삼성전자 주식회사 | Analog switch circuit |
US5278146A (en) * | 1988-09-30 | 1994-01-11 | The Salk Institute For Biological Studies | CRF analogs |
US4857533A (en) * | 1988-12-15 | 1989-08-15 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for autoimmune diseases |
FR2646347B1 (en) * | 1989-04-28 | 1991-08-23 | Roussel Uclaf | NOVEL HYDROXYPHENETHYLAMINE DERIVATIVE AND ITS SALTS, METHOD OF PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS A SPECIFIC PHARMACOLOGICAL TOOL |
US5017689A (en) * | 1989-07-06 | 1991-05-21 | Arizona Technology Development Corporation | Dynorphin analogs specific for kappa opioid receptors |
US5096715A (en) * | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
JP2906654B2 (en) * | 1989-11-28 | 1999-06-21 | 東レ株式会社 | Immunosuppressant and method for producing the same |
US5013740A (en) * | 1990-03-22 | 1991-05-07 | Hillel Glover | Method for treating emotional numbness and coma |
US5028612A (en) * | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
US5616562A (en) * | 1990-04-27 | 1997-04-01 | Murphy; Christopher J. | Methods and compositions using substance P to promote wound healing |
US5137873A (en) * | 1990-07-27 | 1992-08-11 | The Children's Medical Center Corporation | Substance p and tachykinin agonists for treatment of alzheimer's disease |
GB9202238D0 (en) * | 1992-02-03 | 1992-03-18 | Wellcome Found | Compounds |
US6271239B1 (en) * | 1992-04-13 | 2001-08-07 | Regents Of The University Of Minnesota | Delta opioid receptor-selective benzylidene-substituted morphinans |
US5326751A (en) * | 1992-06-26 | 1994-07-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Enkephalin analogs |
SE9203496D0 (en) * | 1992-11-20 | 1992-11-20 | Kabi Pharmacia Ab | NEW OLIGOPEPTIDES |
US5817628A (en) * | 1992-12-02 | 1998-10-06 | The Rockefeller University | Dynorphin a suppression of natural killer cell activity |
US6369074B1 (en) * | 1992-12-10 | 2002-04-09 | Pfizer Inc. | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists |
SE9300012D0 (en) * | 1993-01-05 | 1993-01-05 | Astra Ab | NEW PEPTIDES |
FR2700472B1 (en) * | 1993-01-19 | 1995-02-17 | Rhone Poulenc Rorer Sa | Synergizing association having an antagonistic effect on the NK1 and NK2 receptors. |
US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
US5891842A (en) * | 1993-04-09 | 1999-04-06 | Trustees Of Tufts College | Methodology for eliciting an analgesic response in a living subject |
US6096513A (en) * | 1993-05-20 | 2000-08-01 | Arch Development Corporation | Polynucleotides encoding KAPPA opiod receptors |
US5457208A (en) * | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
US5395398A (en) * | 1993-07-28 | 1995-03-07 | C. R. Bard, Inc. | Microelectric apparatus for the antisepsis, promulgation of healing and analgesia of wound and chronic skin ulcers |
US5411965A (en) * | 1993-08-23 | 1995-05-02 | Arizona Board Of Regents | Use of delta opioid receptor antagonists to treat cocaine abuse |
US5464841A (en) * | 1993-11-08 | 1995-11-07 | Univ Minnesota | Use of delta opioid receptor antagonists to treat immunoregulatory disorders |
SE9503924D0 (en) * | 1995-08-18 | 1995-11-07 | Astra Ab | Novel opioid peptides |
IT1269826B (en) * | 1994-05-24 | 1997-04-15 | Paolo Minoia | USE OF OPTIACEAN ANTAGONISTS AND CALCIUM SALTS FOR THE PREPARATION OF MEDICATIONS FOR THE TREATMENT OF ENDORPHINE-MEDIATED PATHOLOGICAL FORMS |
PT1221440E (en) * | 1994-06-15 | 2007-07-20 | Otsuka Pharma Co Ltd | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators |
CA2194984C (en) * | 1994-07-26 | 2002-07-02 | John Eugene Macor | 4-indole derivatives as serotonin agonists and antagonists |
JPH10513471A (en) * | 1995-02-10 | 1998-12-22 | メドトロニック、インコーポレイテッド | Methods and devices for the administration of analgesics |
FR2732221B1 (en) * | 1995-03-28 | 1997-04-25 | Oreal | USE OF A CGRP ANTAGONIST TO TREAT CUTANEOUS REDNESS OF NEUROGENIC ORIGIN AND COMPOSITION OBTAINED |
IT1275433B (en) * | 1995-05-19 | 1997-08-07 | Smithkline Beecham Farma | DIARYLDIAMINE DERIVATIVES |
US5610271A (en) * | 1995-06-07 | 1997-03-11 | Torrey Pines Institute For Molecular Studies | Kappa receptor selective opioid peptides |
US6214797B1 (en) * | 1995-06-13 | 2001-04-10 | The Salk Institute For Biological Studies | Urocortin peptides, nucleic acid encoding same methods for using same |
IT1277597B1 (en) * | 1995-09-15 | 1997-11-11 | Smithkline Beecham Spa | DIARYLALKENYLAMINE DERIVATIVES |
AU724993B2 (en) * | 1996-03-13 | 2000-10-05 | Yale University | Smoking cessation treatments using naltrexone and related compounds |
US6737397B1 (en) * | 1996-03-29 | 2004-05-18 | The Penn State Research Foundation | Control of cancer growth through the interaction of [MET5]-enkephalin and the zeta receptor |
AU2898297A (en) * | 1996-05-24 | 1998-01-05 | Novartis Ag | Use of substance p antagonists for treating social phobia |
US5945508A (en) * | 1996-07-23 | 1999-08-31 | Witten; Mark L. | Substance P treatment for immunostimulation |
DE69732570T2 (en) * | 1996-08-02 | 2005-12-29 | Kaneka Corp. | Sulphonic acid derivatives, process for their preparation and their use |
ES2215158T3 (en) * | 1996-11-25 | 2004-10-01 | Toray Industries, Inc. | ANTIPRURITIC AGENT. |
US6440987B1 (en) * | 1996-11-25 | 2002-08-27 | Toray Industries, Inc. | Antipruritic |
EP0946157B1 (en) * | 1996-12-16 | 2002-03-13 | Alcon Laboratories, Inc. | The topical use of kappa opioid agonists to treat ocular pain |
US6025157A (en) * | 1997-02-18 | 2000-02-15 | Genentech, Inc. | Neurturin receptor |
GB9709972D0 (en) * | 1997-05-19 | 1997-07-09 | Pfizer Ltd | Tetrazoles |
US6063758A (en) * | 1997-07-09 | 2000-05-16 | Advanced Targeting Systems, Inc. | Substance P-Saporin (SP-SAP) conjugates and methods of use thereof |
US6194407B1 (en) * | 1997-07-30 | 2001-02-27 | American Home Products Corporation | Tricyclic pyrido vasopressin agonists |
US5922361A (en) * | 1997-08-11 | 1999-07-13 | Bieser; Albert Howard | Folic acid enriched dietary supplement compositions for self-regulating stress-reduction |
EP0974363B1 (en) * | 1997-09-02 | 2005-06-22 | Toray Industries, Inc. | Remedies for drug addiction |
ATE317226T1 (en) * | 1997-10-27 | 2006-02-15 | Cortex Pharma Inc | TREATMENT OF SCHIZOPHRENIA WITH AMPAKINES AND NEUROLEPTICS |
US6437092B1 (en) * | 1998-11-06 | 2002-08-20 | Conjuchem, Inc. | Conjugates of opioids and endogenous carriers |
DK0957099T3 (en) * | 1998-04-15 | 2003-03-17 | Pfizer Prod Inc | Heterocyclic carboxamides |
GB9815618D0 (en) * | 1998-07-18 | 1998-09-16 | Univ Manchester | Treatment of dyskinesia |
US6090803A (en) * | 1998-07-24 | 2000-07-18 | American Home Products Corporation | Tricyclic vasopressin agonists |
ES2150378B1 (en) * | 1998-08-07 | 2001-07-01 | Esteve Labor Dr | EMPLOYMENT OF ARIL (OR HETEROARIL) AZOLILCARBINOLES DERIVATIVES IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISORDERS MEDIATED BY AN EXCESS OF SUBSTANCE P. |
US6436959B1 (en) * | 1998-12-23 | 2002-08-20 | Ortho-Mcneil Pharmaceutical, Inc. | 4-[aryl(piperidin-4-yl)]aminobenzamides |
US6235900B1 (en) * | 1999-02-04 | 2001-05-22 | American Home Products Corporation | Tricyclic pyridine N-oxides vasopressin agonists |
US6297234B1 (en) * | 1999-02-04 | 2001-10-02 | American Home Products Corporation | Arylthiophene vasopressin agonists |
US6344451B1 (en) * | 1999-02-04 | 2002-02-05 | American Home Products | Pyrrolobenzodiazepine carboxyamide vasopressin agonists |
GB9907571D0 (en) * | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Compounds |
IT1312083B1 (en) * | 1999-04-20 | 2002-04-04 | Smithkline Beecham Spa | MORPHINOID DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND THERAPEUTIC USE. |
IT1306165B1 (en) * | 1999-07-05 | 2001-05-30 | Innova Ltd | USE OF INHIBITORS OF THE SUBSTANCE P FOR THE TREATMENT OF DENOCARCINOMAS. |
US6384044B1 (en) * | 1999-11-29 | 2002-05-07 | Bernard Bihari | Method of treating cancer of the prostate |
AUPQ514600A0 (en) * | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
BR0108965A (en) * | 2000-03-03 | 2002-11-26 | Ortho Mcneil Pharm Inc | Derivatives of 3- (diarylmethylene) -8-azabicyclo [3,2,1] octane |
ATE326222T1 (en) * | 2000-03-15 | 2006-06-15 | Wolfgang Sadee | NALOXONE AND NALTREXONE ANALOGUES IN DRUG ABUSE TREATMENT |
WO2001093852A2 (en) * | 2000-06-09 | 2001-12-13 | The Regents Of The University Of California | Method of treating pain using nalbuphine and opioid antagonists |
TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
US6596692B1 (en) * | 2000-07-31 | 2003-07-22 | Dabur Research Foundation | Substance P analogs for the treatment of cancer |
US6569449B1 (en) * | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
ATE402179T1 (en) * | 2000-11-22 | 2008-08-15 | Toray Industries | INDOLE DERIVATIVES AND THEIR USE IN MEDICATIONS |
US6437093B1 (en) * | 2000-11-28 | 2002-08-20 | Milkhaus Laboratory, Inc. | Methods of treatment comprising administration of Substance P |
WO2002049643A1 (en) * | 2000-12-21 | 2002-06-27 | The Mclean Hospital Corporation | Treatment of depression |
US6559159B2 (en) * | 2001-02-01 | 2003-05-06 | Research Triangle Institute | Kappa opioid receptor ligands |
US6838580B2 (en) * | 2002-01-29 | 2005-01-04 | Teikoku Seiyaku Co., Ltd. | Opioid derivative |
WO2003066004A2 (en) * | 2002-02-08 | 2003-08-14 | President And Fellows Of Harvard College | Therapeutic compounds |
US7594967B2 (en) * | 2002-08-30 | 2009-09-29 | Amberwave Systems Corporation | Reduction of dislocation pile-up formation during relaxed lattice-mismatched epitaxy |
AU2003275433A1 (en) * | 2002-10-07 | 2004-05-04 | Synergia Pharma, Inc. | Compositions and methods for treating pain |
US7820689B2 (en) * | 2006-08-10 | 2010-10-26 | Hua-Lin Wu | Methods and compositions for preventing or treating cardiovascular disease |
-
2005
- 2005-09-23 CA CA002580694A patent/CA2580694A1/en not_active Abandoned
- 2005-09-23 CN CNA2005800402066A patent/CN101065014A/en active Pending
- 2005-09-23 JP JP2007533610A patent/JP2008514612A/en active Pending
- 2005-09-23 WO PCT/US2005/033826 patent/WO2006034343A2/en active Application Filing
- 2005-09-23 US US11/234,850 patent/US20060069086A1/en not_active Abandoned
- 2005-09-23 AU AU2005286733A patent/AU2005286733B2/en not_active Ceased
- 2005-09-23 EP EP05800810A patent/EP1809104A4/en not_active Withdrawn
-
2010
- 2010-02-18 US US12/708,240 patent/US20100234360A1/en not_active Abandoned
-
2011
- 2011-03-30 JP JP2011075964A patent/JP2011137038A/en active Pending
- 2011-09-13 US US13/231,578 patent/US20120088756A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of EP1809104A4 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7829596B2 (en) | 1998-10-15 | 2010-11-09 | Imperial Innovations Limited | Methods of treatment |
US9422225B2 (en) | 2005-12-01 | 2016-08-23 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
US8138226B2 (en) | 2005-12-01 | 2012-03-20 | Auspex Pharmaceuticals | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
US9458082B2 (en) | 2005-12-01 | 2016-10-04 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
EP2001495A4 (en) * | 2006-02-27 | 2010-12-08 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
EP2001495A2 (en) * | 2006-02-27 | 2008-12-17 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
WO2007131154A3 (en) * | 2006-05-04 | 2008-03-06 | Accelerated Technologies Corp | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
WO2007131154A2 (en) * | 2006-05-04 | 2007-11-15 | Accelerated Technologies Corporation | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
US10421710B2 (en) | 2007-03-15 | 2019-09-24 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
AT505086B1 (en) * | 2007-04-02 | 2009-06-15 | Planta Naturstoffe Vertriebsge | PHARMACEUTICAL AGENT AGAINST JUCKREIZ AND JUCKREIZED PAIN |
US8372414B2 (en) | 2009-12-22 | 2013-02-12 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
US8741319B2 (en) | 2009-12-22 | 2014-06-03 | Pondera Biotechnologies, Inc. | Methods and compositions for treating anxiety disorders or symptoms thereof |
US8617577B2 (en) | 2009-12-22 | 2013-12-31 | Pondera Biotechnologies Inc. | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
US8202525B2 (en) | 2009-12-22 | 2012-06-19 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
CN104955483A (en) * | 2013-01-30 | 2015-09-30 | 法莫斯医疗公司 | Treatments for depression and other diseases with a low dose agent |
US10772871B2 (en) | 2013-10-07 | 2020-09-15 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
US10874642B2 (en) | 2013-10-07 | 2020-12-29 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
US10987342B2 (en) | 2013-10-07 | 2021-04-27 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
Also Published As
Publication number | Publication date |
---|---|
JP2011137038A (en) | 2011-07-14 |
EP1809104A2 (en) | 2007-07-25 |
AU2005286733B2 (en) | 2009-11-05 |
EP1809104A4 (en) | 2009-04-29 |
CA2580694A1 (en) | 2006-03-30 |
CN101065014A (en) | 2007-10-31 |
JP2008514612A (en) | 2008-05-08 |
US20120088756A1 (en) | 2012-04-12 |
US20100234360A1 (en) | 2010-09-16 |
WO2006034343A3 (en) | 2006-10-05 |
US20060069086A1 (en) | 2006-03-30 |
AU2005286733A1 (en) | 2006-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005286733B2 (en) | Methods for regulating neurotransmitter systems by inducing counteradaptations | |
Toce et al. | Pharmacologic treatment of opioid use disorder: a review of pharmacotherapy, adjuncts, and toxicity | |
Hillhouse et al. | A brief history of the development of antidepressant drugs: from monoamines to glutamate. | |
Vocci et al. | Medications development: successes and challenges | |
De Bodinat et al. | Agomelatine, the first melatonergic antidepressant: discovery, characterization and development | |
CA2643802A1 (en) | Methods for regulating neurotransmitter systems by inducing counteradaptations | |
US20120208751A1 (en) | Methods for Regulating Neurotransmitter Systems by Inducing Counteradaptations | |
JP2008507577A (en) | Medicaments for treating disorders of the central nervous system | |
Vearrier et al. | Clinical pharmacology, toxicity, and abuse potential of opioids | |
Rénéric et al. | Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test | |
Sateia et al. | Efficacy and clinical safety of ramelteon: an evidence-based review | |
WO2008083442A1 (en) | Method for formulating combination medications for adhd | |
Levi et al. | A review of chemical agents in the pharmacotherapy of addiction | |
Rénéric et al. | In the rat forced swimming test, NA-system mediated interactions may prevent the 5-HT properties of some subacute antidepressant treatments being expressed | |
Reddy et al. | New medications for neuropsychiatric disorders | |
Schreiber et al. | Trazodone and mirtazapine: A possible opioid involvement in their use (at low dose) for sleep? | |
Kamei et al. | (+)-SKF-10,047 and dextromethorphan ameliorate conditioned fear stress via dopaminergic systems linked to phenytoin-regulated σ1 sites | |
Arias et al. | Interaction of nicotinic receptors with bupropion: Structural, functional, and pre-clinical perspectives | |
JP2012500248A (en) | Treatment of anxiety disorder | |
Ikram et al. | Neurochemical and behavioral effects of midazolam: A dose related study. | |
McMahon et al. | Discriminative stimulus effects of (−)-ephedrine in rats: analysis with catecholamine transporter and receptor ligands | |
MXPA06002504A (en) | The combination of a serotonin reuptake inhibitor and loxapine. | |
Mody et al. | In search of novel and therapeutically significant melatoninergic ligands | |
Schifano | Drug abuse: treatment and management | |
CA2643922A1 (en) | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2580694 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007533610 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1043/KOLNP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005286733 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005286733 Country of ref document: AU Date of ref document: 20050923 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005286733 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005800810 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580040206.6 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005800810 Country of ref document: EP |